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DNA methylation plays a crucial role in human health, especially cancer. Traditional
DNA methylation analysis aims to identify CpGs/genes with differential methylation (DM)
between experimental groups. Differential variability (DV) was recently observed that con-
tributes to cancer heterogeneity and was also shown to be essential in detecting early DNA
methylation alterations, notably epigenetic field defects. Moreover, studies have demon-
strated that environmental factors may modify the effect of DNA methylation on health
outcomes, or vice versa. Therefore, this dissertation seeks to develop new statistical meth-
ods for epigenetic data focusing on DV and interactions when efficient analytical tools are
lacking. First, as neighboring CpG sites are usually highly correlated, we introduced a new
method to detect differentially methylated regions (DMRs) that uses combined DM and
DV signals between diseased and non-diseased groups. Next, using both DM and DV sig-
nals, we considered the problem of identifying epigenetic field defects, when CpG-site-level
DM and DV signals are minimal and hard to be detected by existing methods. We pro-
posed a weighted epigenetic distance-based method that accumulates CpG-site-level DM
and DV signals in a gene. Here DV signals were captured by a pseudo-data matrix con-
structed using centered quadratic methylation measures. CpG-site-level association signal
annotations were introduced as weights in distance calculations to up-weight signal CpGs
and down-weight noise CpGs to further boost the study power. Lastly, we extended the
weighted epigenetic distance-based method to incorporate DNA methylation by environ-
ment interactions in the detection of overall association between DNA methylation and
health outcomes. A pseudo-data matrix was constructed with cross-product terms between
DNA methylation and environmental factors that is able to capture their interactions. The
superior performance of the proposed methods were shown through intensive simulation
studies and real data applications to multiple DNA methylation data.
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DNA methylation plays a crucial role in human health, especially cancer. A typical analysis
of DNA methylation involves identification of differentially methylated (DM) CpG sites
or genes between different experimental groups, when traditional DM analysis aims to
identify CpGs/genes with significant changes in mean methylation levels between different
experimental groups, such as diseased and non-diseased samples. Differential variability
(DV) was recently observed that contributes to cancer heterogeneity and was also shown
to be essential in detecting DNA methylation alterations happening early in carcinogenesis,
namely epigenetic field defects. In analysis of DV, the aim is to identify CpGs/genes with
a significant change in variance of methylation levels between two experimental groups.
Moreover, studies have demonstrated that environmental factors may modify the effect of
DNA methylation on health outcomes, or vice versa. Therefore, this dissertation seeks to
develop new statistical methods for epigenetic data focusing on DV and interactions when
efficient analytical tools are lacking.
First, as neighboring CpG sites are usually highly correlated, we introduced a new
method to detect differentially methylated regions (DMRs) that uses combined DM and DV
signals between diseased and non-diseased groups. This work found that the proposed DMR
method is much more powerful than existing methods that use either DM or DV signals
when both signals exist. Applications to DNA methylation data of breast invasive carcinoma
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(BRCA) and kidney renal clear cell carcinoma (KIRC) from The Cancer Genome Atlas
(TCGA) and another DNA methylation data of BRCA from Gene Expression Omnibus
(GEO) suggest that the proposed DMR method identified new cancer-related DMRs that
were missed by methods considering only one type of signals. The two BRCA datasets
allowed us for a replication analysis which suggests that the identified DMRs based on DV
signals are reproducible.
Next, using both DM and DV signals, we considered the problem of identifying epi-
genetic field defects, when both DM and DV signals are minimal on CpG site levels and
won’t be detected by existing methods. We proposed a weighted epigenetic distance-based
method accumulating both CpG-site-level DM and DV signals in a gene. Here DV signals
were captured by a pseudo-data matrix constructed using centered quadratic methylation
measures. CpG-site-level weights were introduced in distance calculations to up-weight sig-
nal CpGs and down-weight noise CpGs to further boost the study power. This work found
that the proposed weighted epigenetic distance-based method has much greater power than
non-weighted versions and site-level epigenome-wide association studies (EWAS). The ap-
plication to the same GEO BRCA methylation data comparing normal-adjacent tissues to
tumors of breast cancer patients (as a surrogate to pre-cancer tissues) to normal tissues of
independent age-matched cancer-free women identified novel epigenetic field defects that
were missed by comparison methods. Majority of the epigenetic field defects identified were
previously reported to be associated with breast cancer and were confirmed the progression
to breast cancer with some of them being further replicated.
Lastly, we extended the weighted epigenetic distance-based method to incorporate DNA
methylation by environment interactions in the detection of overall association between
DNA methylation and health outcomes. In this weighted epigenetic distance-based method,
a pseudo-data matrix was constructed with cross-product terms between DNA methylation
and environmental factors capturing their interactions. Weights were similarly considered
to up-weight signals and down-weight noises in distance calculations. We demonstrated the
superior performance of the proposed method over comparison methods. Applications to
the data from the Mothers and Newborns birth cohort of the Columbia Center for Children’s
Environmental Health (CCCEH) identified associations between Attention Deficit Hyper-
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activity Disorder and Mental Development Index at age 3 and several epigenetic genes due
to interaction effects between DNA methylation and prenatal air polycyclic aromatic hy-
drocarbons (PAH) exposure when some of the genes identified were further replicated in
the CCCEH replication data.
1.2 DNA methylation
DNA methylation is an epigenetic modification when methyl groups are added to the 5th
position of cytosine within the CpG dinucleotide (Bird, 2002). It plays an essential role in
gene expression (Baylin et al., 2001; Fahrner et al., 2002; Jones, 2012; Phillips, 2008) and
cancer (Das and Singal, 2004; Ehrlich, 2002; Esteller and Herman, 2002; Kulis and Esteller,
2010). Studies have found that abnormal DNA methylation processes are related to many
different types of cancers (Ruike et al., 2010; Teschendorff et al., 2009; Lasseigne et al., 2014;
Hinoue et al., 2012). In general, two kinds of abbrent methylation are observed. One is local
hyper-methylation which usually occurs in the promoter-related CpG island, and it often
leads to the silence of downstream tumor suppressor genes (Koukoura et al., 2014; Baylin,
2005; Curradi et al., 2002; Herman and Baylin, 2003; Robertson, 2005). The other is global
hypo-methylation that usually leads to instability of chromosomes (Robertson, 2005; Eden
et al., 2003; Feinberg and Tycko, 2004; Jaenisch and Bird, 2003). In addition to cancers,
research also found that aberrant DNA methylation is related to a range of other human
diseases (Feinberg, 2007; Jager et al., 2014; Lund et al., 2004; Mill and Petronis, 2007, 2008;
Mill et al., 2008; Nestler, 2014; Schanen, 2006), such as Alzheimer’s disease (Jager et al.,
2014), major depressive disorder (Mill and Petronis, 2007), drug addiction (Nestler, 2014),
etc.
There are different methods to quantify DNA methylation, among which Bisulfite mi-
croarray and sequencing are two widely used technologies. This includes popular array
technologies including the Illumina Infinium HumanMethylation 27K, 450K and 850K EPIC
BeadChips with methylation β-values measuring the proportion of methylated intensities
out of total intensities. Popular sequencing technologies include whole-genome bisulfite
sequencing, reduced representation bisulfite sequencing and Agilent SureSelect Human
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Methyl-Seq (Methyl-seq), which generate either ratio of methylated intensities versus total
coverage at each CpG site or number of methylated or unmethylated cytosine.
1.3 Statistical methods in DNA methylation studies
Numerous methods were already developed to identify differentially methylated loci (DML)
based on differences in mean methylation levels (DM, mean signals) between two experi-
mental groups. Standard EWAS that focus on mean signals perform CpG site-level tests
to identify differentially methylated CpGs between two experimental groups using standard
tests such as a t-test, a regression-based test or its regularized versions (Tusher et al., 2001;
Smyth, 2004; Wettenhall and Smyth, 2004), or a non-parametric Wilcoxon rank sum test.
Studies have also found that epigenetic instability of important genomic regions may lead
to increased methylation variability in cancer, which also contribute to cancer heterogeneity
(Phipson and Oshlack, 2014; Hansen et al., 2011a; Feinberg and Irizarry, 2010; Gervin et al.,
2011; Jaffe et al., 2012a). Methods were developed to identify differential variability (DV,
variance signals), i.e., CpGs sites with significant differences in variance of methylation
levels between two experimental groups, using standard tests such as an F -test (Hansen
et al., 2011b; Ho et al., 2008), the Bartlett’s test or its regularized versions (Teschendorff
et al., 2016a,b), or an empirical Bayes extension of the Levene’s test (Phipson and Oshlack,
2014). Methods were also developed to identify CpGs with mean and variance combined
signals at CpG site-level (Ahn and Wang, 2013; Chen et al., 2014; Ruan et al., 2016; Sun
et al., 2017).
As DNA methylation levels of neighboring CpGs are strongly correlated, especially
when consecutive CpGs in a genomic region are associated with health outcomes, statistical
methods to detect differentially methylated regions (DMRs) were also developed. Existing
DMR detection methods can be generally grouped into three types, to detect site-level
signals first and then group adjacent loci into regions using ad hoc grouping rules (Hansen
et al., 2012; Jaffe et al., 2012b; Butcher and Beck, 2015; Jühling et al., 2016; Hesse et al.,
2015; Wen et al., 2016); or to define regions first and then test the significance of the defined
regions (Ayyala et al., 2015; Sofer et al., 2013; Yip et al., 2014; Mayo et al., 2014); or to
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use hidden Markov model that assumes three latent methylation states: hyper-methylation,
hypo-methylation and no differential methylation, and then group adjacent sites with the
same state into a region (Saito and Mituyama, 2015; Saito et al., 2014). However, existing
DMR detection methods all focus on mean signals only.
1.4 Epigenetic field defects
Epigenetic field defects are notably DNA methylation alterations that usually occur in pre-
cancer tissues and are crucial in cancer research because of its potential usage in early cancer
detection (Teschendorff et al., 2016a,b). Current studies detecting epigenetic field defects
usually compare normal tissues of healthy individuals to normal tissues adjacent to tumors
(normal-adjacent tissues) of cancer patients as a surrogate of pre-cancer tissues that are
difficult to collect.
Studies have successfully identified epigenetic field defects in breast cancer by comparing
normal-adjacent tissues of breast cancer patients to normal tissues from healthy individuals.
Teschendorff et al. identified epigenetic field defects in breast cancer based on DV signals
with methylation site-level analyses (Teschendorff et al., 2016a).
In chapter 2, we developed a new DMR detection method that combines both DM and
DV signals and successfully applied the developed method in identifying epigenetic field
defects in breast cancer. Similarly as what was observed in Teschendorff et al.(Teschendorff
et al., 2016a), epigenetic field defects were found to be mainly driven by increased variation
in methylation due to several outlier normal-adjacent tissue samples.
1.5 Distance-based method
Distance-based method was originally developed in the field of ecology (McArdle and An-
derson, 2001; Anderson, 2001) and had been proven to be powerful in genetic and gene
expression studies (Zapala and Schork, 2006; Wessel and Schork, 2006; Han and Pan, 2010).
A fundamental step is to construct a distance matrix to characterize the dissimilarities be-
tween pairs of individual samples in a study. It always has a dimension of N × N with
N being the sample size regardless the added dimensionality from additional information
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collected on the samples under the study.
Since epigenetic field defects are often characterized by increased variation in DNA
methylation measures due to a few outlier normal-adjacent tissue samples, standard EWAS
that perform CpG site-level tests are usually underpowered due to small mean differences as
well as stringent multiple comparisons adjustment in a gene or a genetic region level. The
common practice is to conduct site-level tests and select the site with minimum P -value in
the region studied. These methods will have low power when site-level effects are minimal.
On the other hand, distance-based methods accumulate site-level signals across all CpGs
in a gene or a genetic region in calculating gene-level distances between pairs of samples
thus boost the overall association power. This makes the distance-based methods the ideal
methods to detect epigenetic field defects. In addition, distance-based methods are flexible
and can be applied to a CpG site, a gene, a pathway, or an entire genome.
In chapter 3, we developed a weighted epigenetic distance-based method with a pseudo-
data matrix constructed with centered quadratic methylation measures that is able to cap-
ture DV signals. By combining the original data matrix with the pseudo-data matrix, we are
able to accumulate weak CpG-site-level DM and DV signals in a gene. CpG-site-level asso-
ciation signal annotations were introduced as weights in distance calculations to up-weight
signal CpGs and down-weight noise CpGs to further boost the study power.
1.6 Interactions between DNA methylation and Environmen-
tal factors
Studies have demonstrated that DNA methylation may modify the risk of environmental
factors on health outcomes. To identify interaction effects between DNA methylation and
environmental factors on health outcomes has always been a great interest to researchers.
Conventional methods such as EWAS usually focus on examining DM at CpG level or
gene level combining multiple CpGs and/or finding environmental effects on health out-
comes. Due to high dimensionality and low study power, current studies usually ignore the
interaction between DNA methylation and environmental factors.
In chapter 4, we extended the weighted epigenetic distance-based method to incorpo-
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rate DNA methylation by environment interactions. We introduced a pseudo-data matrix
constructed with cross-product terms between DNA methylation and environmental factors
that is able to capture their interaction signals. By combining the original data matrix
with the pseudo-data matrix for interaction effects, we are able to identify both main and
interaction signals. Weights were similarly considered to up-weight signals and down-weight
noises in distance calculations.
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DNA methylation plays an important role in gene expression (Baylin et al., 2001; Fahrner
et al., 2002; Jones, 2012; Phillips, 2008) and cancer (Das and Singal, 2004; Ehrlich, 2002; Es-
teller and Herman, 2002; Kulis and Esteller, 2010). Two types of aberrant DNA methylation
in cancer have been frequently observed, local hyper-methylation in some promoter-related
CpG islands that often leads to silencing of downstream tumor suppressor genes (Kouk-
oura et al., 2014; Baylin, 2005; Curradi et al., 2002; Herman and Baylin, 2003; Robertson,
2005), and global hypo-methylation that usually cause instability of chromosomes (Robert-
son, 2005; Eden et al., 2003; Feinberg and Tycko, 2004; Jaenisch and Bird, 2003). Studies
have found that abnormal DNA methylation processes are related to many cancer types
(Ruike et al., 2010; Teschendorff et al., 2009; Lasseigne et al., 2014; Hinoue et al., 2012)
and a range of other human diseases (Feinberg, 2007; Jager et al., 2014; Lund et al., 2004;
Mill and Petronis, 2007, 2008; Mill et al., 2008; Nestler, 2014; Schanen, 2006). Studies have
also found that epigenetic instability of important genomic regions may lead to increased
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methylation variability in cancer, which also contribute to cancer heterogeneity (Phipson
and Oshlack, 2014; Hansen et al., 2011a; Feinberg and Irizarry, 2010; Gervin et al., 2011;
Jaffe et al., 2012a). A study examining DNA methylation profiles of 1,505 CpG sites of both
normal tissues and tumorigenic tissues observed that there is little variation in the DNA
methylation patterns of these normal tissues but greater methylation heterogeneity among
tumors (Fernandez et al., 2012). Studies have successfully identified epigenetic field defects
in breast cancer based on differential variability (DV) (Teschendorff et al., 2016a). Epige-
netic field defects are notably DNA methylation alterations that usually occur in pre-cancer
tissues (Slaughter et al., 1953) and are crucial in cancer research because of its potential
usage in early cancer detection (Teschendorff et al., 2016a,b).
Bisulfite microarray and sequencing are two widely used technologies to quantify DNA
methylation. Popular array technologies include Illumina Infinium HumanMethylation 27K,
450K and 850K EPIC BeadChips, which produce methylation β-values measuring the pro-
portion of methylated intensities out of total intensities. Popular sequencing technologies
include whole-genome bisulfite sequencing, reduced representation bisulfite sequencing and
Agilent SureSelect Human Methyl-Seq (Methyl-seq), which generate either ratio of methy-
lated intensities versus total coverage at each CpG site or number of methylated or un-
methylated cytosine.
Methods to identify differentially methylated loci (DML) based on differences in mean
methylation levels between two groups are well-studied (Akalin et al., 2012; Chen et al.,
2013; Huang et al., 2013; Shen et al., 2012; Sun and Wang, 2012, 2013). As DNA methyla-
tion levels of neighboring CpG sites are strongly correlated (Eckhardt et al., 2006; Irizarry
et al., 2008) when genomic regions with consecutive CpG sites are associated with cancers
(Hansen et al., 2011a; Irizarry et al., 2009; Lister et al., 2009), methods to detect differen-
tially methylated regions (DMRs) were also developed. However, existing DMR detection
methods all focus on mean signals only, and can be generally grouped into three types, to
detect site-level signals first and then group adjacent loci into regions using ad hoc grouping
rules (Hansen et al., 2012; Jaffe et al., 2012b; Butcher and Beck, 2015; Jühling et al., 2016;
Hesse et al., 2015; Wen et al., 2016); or to define regions first and then test the significance
of the defined regions (Ayyala et al., 2015; Sofer et al., 2013; Yip et al., 2014; Mayo et al.,
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2014); or to use hidden Markov model that assumes three latent methylation states: hyper-
methylation, hypo-methylation and no differential methylation, and then group adjacent
sites with the same state into a region (Saito and Mituyama, 2015; Saito et al., 2014). For
array data, for example, bumphunter (Jaffe et al., 2012b) uses surrogate variable analysis
to account for potential batch effects, smoothes site-level signals within a predefined win-
dow and defines regions, as adjacent CpG sites with smoothed signals exceed a user-defined
threshold. DMRcate (Peters et al., 2015) uses a tunable Gaussian kernel to smooth site-level
differential methylation signals within a given window, then uses the method of Satterth-
waite (Satterthwaite, 1946) to model the smoothed signals and group neighboring false
discovery rate (FDR)-corrected significant CpG sites into regions. Probe Lasso (Butcher
and Beck, 2015) uses a flexible window based on probe density to gather neighboring sig-
nificant signals to define DMR boundaries. For Bisulfite sequencing data, for example,
metilene (Jühling et al., 2016) uses a binary segmentation algorithm to identify candidate
DMRs and then use a two-dimensional Kolmogorov-Smirnov (KS) test to assess the signif-
icance of candidate DMRs. MethylKit (Akalin et al., 2012) applies logistic regression to
predefined regions after normalizing the read coverage across samples. Specific Methyla-
tion Analysis and Report Tool (SMART) (Liu et al., 2015) is an entropy-based framework
that first calculates Tukey biweight to quantify methylation specificity at each CpG site,
then uses specificity state, Euclidean distance-based methylation similarity, entropy-based
methylation similarity and minimum distance requirement to indicate whether methyla-
tion patterns of two neighboring CpG sites are similar and then determines DMRs. All of
these existing DMR detection methods use mean signals only. In addition to differential
methylation, which refers to the difference between mean methylation measures between ex-
perimental groups, methods to identify DV, that is, experimental groups differ in terms of
methylation variances, were also developed (Phipson and Oshlack, 2014; Teschendorff et al.,
2016a; Ahn and Wang, 2013; Chen et al., 2014; Teschendorff et al., 2014; Teschendorff and
Widschwendter, 2012; Ruan et al., 2016). We recently developed NEpiC and pETM meth-
ods where NEpiC is a network-based method that combines both mean and variance signals
with a much improved power in searching for differentially methylated subnetworks using
the protein-protein interaction network (Ruan et al., 2016); pETM is a penalized Exponen-
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tial Tilt Model that detects both methylation mean and variance signals at CpG site level
with the network-based regularization considering correlations among nearby CpGs (Sun
et al., 2017). The study that identified epigenetic field defects in breast cancer through
comparing DNA methylation levels in normal tissues adjacent to tumors (normal-adjacent)
as a surrogate of pre-cancer tissues with those in normal tissues from healthy individuals
would have erroneously concluded that there are no significant epigenetic field defects in
breast cancer had the authors used a statistical method based on differential methylation
only (Teschendorff et al., 2016a). The authors also observed increased variation in the
normal-adjacent tissues driven by a relatively small number of outlier samples exhibiting
much-different methylation values from the rest of the normal-adjacent samples (Teschen-
dorff et al., 2016a), when conventional methods focused on mean signals are not able to
detect such epigenetic alterations. On region levels, a new method that incorporates DV is
needed, especially in detecting epigenetic field defects.
Here, we developed a new DMR detection method that uses combined signal from dif-
ferential methylation and DV. Simulation studies showed the great performance of the new
method. We further demonstrated the performance of the new method through applications
to 450K DNA methylation data of tumor and normal-adjacent tissues of breast invasive car-
cinoma (BRCA) and kidney renal clear cell carcinoma (KIRC) from The Cancer Genome
Atlas (TCGA) project, where some cancer-related genes were missed by the DMR detection
methods that use only mean signals or variance signals. By applying the new method to
an independent 450K DNA methylation data of BRCA tumor and normal-adjacent tissues
from Gene Expression Omnibus (GEO), we concluded that DMRs detected using vari-
ance signals are reproducible. Further applications to the GEO DNA methylation data
comparing normal-adjacent tissues from breast cancer patients and normal tissues from
age-matched cancer-free women and comparing tumor tissues from breast cancer patients
to normal tissues from age-matched cancer-free women not only identified epigenetic field
defects in breast cancer but also confirmed that the epigenetic field defects are enriched in
the progression to breast cancer (Teschendorff et al., 2016a). Importantly, the epigenetic
field defects were only identified by the developed new DMR detection method that uses
mean and variance combined signals.
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Figure 2.1: The pipeline of the proposed new DMR detection algorithm.
2.2 Methods
As matched case-control study designs with tumor and normal-adjacent tissues are widely
used in DNA methylation studies of cancer; here, we focused on studies with a matched
case-control design. The proposed new DMR detection method can be easily adapted to
other types of designs. There are four steps in the new method (Figure 2.1): (1) define
site-level mean and variance combined signal scores; (2) smooth site-level combined signal
scores; (3) identify candidate DMRs; and (4) assess significance of candidate DMRs.
Step 1: Define site-level mean and variance combined signal scores




(λmi + (1− λ)vi) (2.1)
where mi = Φ
−1(1 − pmi) and vi = Φ−1(1 − pvi). Here, Φ is standard normal quantile
function, and pmi and pvi are P -values from the two-sided paired t-test testing if the mean
methylation measures are the same between tumor and normal-adjacent tissues and from
the one-sided Pitman-Morgan test testing if the variance of the methylation measures in
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tumor tissues is greater than that in normal-adjacent tissues at CpG site i (Morgan, 1939;
Pitman, 1939), respectively. We set mean and variance signal scores that are smaller than
zero (i.e. sites with pmi > 0.5 and pvi > 0.5) as zero and remove sites whose mean and
variance signal scores are both zero. Here, Tmi is the test statistic from a paired t-test,
where |Tmi|Tmi adds a sign to the combined signal score to indicate whether CpG site i is
hyper-methylated (positive sign) or hypo-methylated (negative sign). Similarly, as in our
previous work (Ruan et al., 2016), because of potential different scales of the site-level mean
and variance signal scores mi and vi, we weight the two scores by λ and 1−λ, respectively,
to balance the contribution of mean and variance signals to the combined score. We first





At CpG site i, we then average across all sites from the whole genome to obtain the
overall scaling parameter λ.
Step 2: Smooth site-level combined signal scores
As methylation levels of CpG sites within 1,000 base pairs (bps) are considered highly cor-
related (Eckhardt et al., 2006; Sofer et al., 2013), we assign any two neighboring CpG sites
into the same cluster if the genomic distance between them is <1,000 bps. We examined
how neighboring CpG sites with different distance limits differ in the combined signal scores
and summarized results in the Supplementary Data (Section A.1 Investigation of the dis-
tance limits to define clusters). We then smooth site-level combined signal scores within
a defined cluster using the running median method with a window size of minimum of W
sites. The running median method was chosen over the moving average (Wu et al., 2015)
method because of its robustness to outliers. It was chosen over regression-based smoothing
methods (Hansen et al., 2012; Jaffe et al., 2012b), which have been shown to have similar
performance as the moving averaging method (Wu et al., 2015) because of its computational
efficiency. After smoothing, we denote the smoothed combined signal score for CpG site i
as S̃i.
Step 3: Identify candidate DMRs
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A candidate DMR is defined to be a region having at least L consecutive CpG sites of the
same sign with |S̃i| > k, where L is a predefined number, and k is a predefined threshold,
e.g. the region size to be L ≥ 3 CpG sites and the threshold to be k = 99th percentile of
genome-wide |S̃i|. Similar criteria of k (Hansen et al., 2012; Jaffe et al., 2012b; Wu et al.,
2015; Hebestreit et al., 2013) and L (Hansen et al., 2012; Wu et al., 2015) were used in
other DMR detection methods.
Step 4: Assess significance of candidate DMRs
We use permutation procedures to assess the significance of candidate DMRs, where we
use the following measure to evaluate the strength of evidence for the jth candidate DMR
Rj : Aj =
∑
i∈Rj |S̃i|. To assess the significance of the candidate DMR Rj via a permuta-
tion procedure under the global null hypothesis adjusting for multiple comparisons, we first
shuffle tumor and normal-adjacent status within all pairs and then apply Steps 1-3 to the
permuted data set. For the gth permutation that generates ng regions, we have the evidence
of strength for each region as follows: Apermg ,t, t = 1, ..., ng. We repeat the permutation






t=1 I(Apermg ,t > Aj)∑1000
g=1 ng
(2.3)
To account for multiple comparisons, we calculate the family-wise error rate (FWER) for
the candidate DMR Rj as the proportion of permutations with maxt∈[1,ng ](Apermg ,t) > Aj .
The candidate DMR Rj is then considered to be significant if its FWER≤ 0.05.
The new method outputs a table of candidate DMRs with detailed information of each
candidate DMR Rj : (1) chromosome location, (2) genomic locations of the first and last
CpG sites, (3) strength of evidence Aj , (4) number of CpG sites, (5) unadjusted P -value
Pj and (6) FWER. Users could also output intermediate results such as mean signal scores
and variance signal scores of CpG sites before smoothing as an option.
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2.3 Comparison methods
We compared the performance of the new method that combines mean and variance signals
with those of the DMR detection methods that (1) consider mean signals only including
the adapted bump hunting algorithm using two-sided paired t-test, DMRcate, Probe Lasso
and the adapted new method with the test statistic from Wilcoxon signed-rank test as the
nonparametric version of the mean signals, (2) variance signals only which is the adapted
bump hunting algorithm using one-sided Pitman-Morgan test and (3) both mean and vari-
ance signals (the adapted new method with test statistic from KS test).
2.4 Simulation study
We conducted simulation studies to evaluate type I errors and the performance of the new
method. We define type I errors as the proportions of simulations identified any significant
DMRs when data are generated with no DMRs. We use receiver operating characteristic
(ROC) curves to evaluate the performance of the new method where we define true positive
as significant DMRs with any CpG sites that are in the true DMRs and false positive as
significant DMRs with no CpG sites from the true DMRs.
2.4.1 Simulation setup
To simulate methylation measures for tumor and normal-adjacent tissues, we considered
1:1 matched study design with one tumor sample (Y = 1) and one normal-adjacent sample
(Y = 0) on the matching variable Z. Given Y and Z, we assume logit2 transformed
methylation measures (Du et al., 2010) X follows a conditional scaled normal distribution:
X|Y = 1, Z = z ∼
√
zN(µ,∆TΣ∆)
X|Y = 0, Z = z ∼
√
zN(0,Σ)
where the matching variable Z ∼ Beta(a, b) and Σ is a variance-covariance matrix con-
sidering correlations among CpG sites within a predefined cluster. The mean vector µ =
(µ1, ..., µh)




δh) control the mean and variance
signals in a cluster of h consecutive sites. Here, we assume an AR(1) correlation with corre-
lation coefficient ρ, i.e. Σmn = σ×ρ|m−n|. We set ρ = 0.5 and Z ∼ Beta(1, 1) in simulation
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studies based on our previous experience (Sun and Wang, 2013). In each simulation, we
generated X of 10,000 CpG sites from 100 tumor and normal-adjacent pairs, where the
genomic locations of these 10,000 sites are the first 10,000 sites of Chromosome 1 on the
Illumina 450K array.
To evaluate type I errors, we set µ = 0, σ = 0.3, where σ was estimated using methy-
lation measures of the normal-adjacent tissues of the TCGA BRCA data. To evaluate the
performance of the new method, we simulated 10 true DMRs with different sizes, varying
from 3 to 15 CpG sites, and we considered scenarios when each CpG site in the true DMRs
has (1) mean signals only, (2) variance signals only and (3) both mean and variance signals.
For all other null CpG sites, we set µ = 0 and σ = 0.3. For each simulation scenario,
we conducted 1,000 simulations. In all simulation studies and real data applications, we
defined the region size to be L ≥ 3 CpG sites.
2.4.2 Adaption to case-control designs
We adapted the proposed new DMR detection method for case-control designs, which can
adjust for relevant covariates. More specifically, we fit a linear regression model on logit2
transformed methylation β-values, M -values, adjusting for known confounders such as age
and gender, and cell composition if necessary, and work on residuals in all subsequent steps.
We conducted simulation studies parallel as for matched case-control designs to evaluate
the type I errors and the performance. The simulation setup and results are summarized
in the Supplementary Data (Section A.2 Simulation studies for case-control designs).
2.5 Results
2.5.1 Simulation results
Type I errors are all well controlled at the 0.05 significance level with values 0.055, 0.046,
0.050, 0.041 and 0.041 for the new method, DMR methods based on paired t-test, Pitman-
Morgan test, Wilcoxon signed-rank test and KS test, respectively, while that for DMRcate
and Probe Lasso are much more conservative with values 0.015 and 0, respectively.
For the ROC curve results (Figure 2.2), when the significance threshold was set from 0
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to 0.05, we notice that when the true DMRs are set to have sites with mean signals only,
the new method performs slightly inferior to paired t-test and similarly to KS test, and
much better than the Wilcoxon signed-rank test, while Pitman-Morgan test that considers
variance signals only could not detect any true DMRs. On the other hand, DMRcate
appears to perform better than the new method with higher true-positive rates and zero
false-positive rates. This is because DMRcate uses Stouffer transformation (Stouffer et al.,
1949) of the limma-derived FDRs for individual CpG sites constituting a DMR to assess
the overall significance of the DMR, which in general is much smaller than the P -values by
the new method assessing significance of candidate DMRs via 1,000 permutations. We also
noticed that DMRcate may not be able to identify regions with small effect sizes comparing
with t-test (with true-positive rates up to around 6 of the 10 regions with signals, while true-
positive rates for t-test could be up to around 8); Probe Lasso also has small false-positive
rates, but the true-positive rates are smaller than that of the new method, and it also uses
Stouffer’s method to combine weighted individual P -values, and thus also leads to much
smaller P -values for DMRs compared with the new method. Similarly, when the true DMRs
are set to have sites with variance signals only, the new method performs slightly inferior
to Pitman-Morgan test that considers variance signals only while all other five comparison
methods could not detect any true DMRs. When the true DMRs are set to have sites with
both mean and variance signals, the new method performs much better than all of the six
comparison methods.
The type I errors and ROC curve results of the adapted algorithm are summarized in
the Supplementary Data (Section A.2 Simulation studies for case-control designs).
2.5.2 Real data application
We used two data sets, TCGA BRCA data (tumor and normal-adjacent pairs) and GEO
BRCA data (tumor and normal-adjacent pairs, normal controls from age-matched cancer-
free women), to demonstrate the performance of the new method from three aspects: (1)
identification of DMRs associated with tumor and normal-adjacent status (TCGA BRCA
tumor versus normal-adjacent comparison; and GEO BRCA tumor versus normal-adjacent
comparison); (2) replication with two independent BRCA data (TCGA BRCA tumor versus
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Figure 2.2: ROC curves from simulation studies where 10 true DMRs have different region sizes
ranging from 3 to 15 CpG sites with (A) mean signals only; (B) variance signals only; and (C) both
mean and variance signals. DMRs were defined as regions with minimum region size of L ≥ 3 CpG
sites.
normal-adjacent comparison; and GEO BRCA tumor versus normal-adjacent comparison);
(3) identification of epigenetic field defects (GEO age-matched cancer-free versus normal-
adjacent comparison); (4) enrichment of epigenetic alterations from age-matched cancer-free
to normal-adjacent to tumor tissues (GEO age-matched cancer-free versus normal-adjacent
comparison, GEO BRCA tumor versus normal-adjacent comparison and GEO age-matched
cancer-free versus tumor comparison).
2.5.3 TCGA BRCA data
We applied the new method and the six comparison methods to the TCGA BRCA 450K
DNA methylation data of tumor and normal-adjacent tissues. The original data have DNA
methylation measures on 485,577 CpG sites for 96 tumor and normal-adjacent pairs. We
conducted standard quality control steps where we removed sites on sex chromosomes and
sites overlap with known single-nucleotide polymorphisms (SNPs). We also required at least
95% CpG coverage per sample and 70% sample coverage per CpG sites. We ended up with
326,105 CpG sites for 90 matched tumor and normal-adjacent pairs. We then corrected for
the type II probe bias using the ‘wateRmelon’ package (Pidsley et al., 2013).
We found that DMRs identified by the Wilcoxon signed-rank test and KS test are larger
than others (both in terms of number of sites and bps) in general, while those by the mean-
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Table 2.2: Eleven genes identified in the top 10 ranked DMRs in TCGA BRCA data
Cancer Gene
Breast cancer LBH (Many and Brown, 2010)
Chordomas NPR3 (Alholle et al., 2015)
Clear cell renal cell carcinoma SMPD3 (Wang et al., 2015)
Gastric cancer FGF19 (Zhao et al., 2013)
Head and neck squamous cell carcinomas PHF21B (Bertonha et al., 2015)
Hepatocellular carcinoma MYADM (Song et al., 2013), DBX2 (Zhang et al., 2013c)
Non-small cell lung cancer KCNC3 (Lokk et al., 2012)
Oral squamous cell carcinoma ATP8B2 (Yong-Deok et al., 2015)
Prostate cancer AQP10 (Raza and Jaiswal, 2013), STEAP2 (Gomes et al., 2012)
only method are the smallest (paired t-test, DMRcate and Probe Lasso), and those by the
new method and Pitman-Morgan test are in between (Table 2.1). On the CpG site level,
69.2, 13.1, 15.4 and 93.6% of sites in the DMRs that were identified by the mean-only
methods: paired t-test, DMRcate, Probe Lasso and Wilcoxon signed-rank test were also
identified by the new method; 83.6% of sites in the DMRs identified by the Pitman-Morgan
test were also identified by the new method, and 77.4% of sites in the DMRs identified
by the KS test were also identified by the new method. Further investigation reveals that
DMRs identified uniquely by the paired t-test and Pitman-Morgan test were all defined by
the new method but did not reach significance.
When comparing DMRs identified by the new method to those by the six comparison
methods, the new method did not identify any unique DMRs. All DMRs identified by
the new method overlap with those identified by DMRcate, where we define overlap if
any CpG sites in a DMR identified by the new method are also in a DMR identified by
DMRcate. When comparing DMRs identified by the new method to those by the five
of the six comparison methods but not DMRcate, the new method uniquely identified 22
DMRs. Among these 22 DMRs, we further examined the top 10 DMRs ranked by the
evidence of strength of each region. There are 11 genes in these 10 DMRs, and all were
previously reported to be associated with cancer (Table 2.2). We plotted the top ranked #1
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Figure 2.3: Top two ranked DMRs uniquely identified by the new method in the TCGA BRCA
data. DMR #1 (top row) and #2 (bottom row) are located on chromosomes 19 and 5. Vertical
dashed lines define boundaries of DMRs. Left column shows the combined signal scores of the sites
in the DMRs before (circles) and after (curves) smoothing, in which horizontal dotted lines define
the threshold k that defines a candidate region. Right column shows the mean differences and SD
ratios in methylation measures of sites in the DMRs comparing tumor and normal-adjacent tissues.
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and #2 DMRs out of the 22 uniquely identified DMRs for illustration (Figure 2.3), where
both DMRs were hyper-methylated. In DMR #1, sites in the second half of the region do
not have any mean differences between tumor and normal-adjacent tissues but have large
variance differences. However, the variance signals are not strong enough to be detected
by the variance-only method. For the sites in the first half of DMR #1, there are both
mean and variance differences, but are not strong enough to be detected by most of the
mean-only or variance-only methods.
We also applied the new method to the TCGA KIRC 450K DNA methylation data,
and observed similar patterns as in the TCGA BRCA data. Results are included in the
Supplementary Data (Supplementary Table A.1 and A.2 and Supplementary Figure A.3).
2.5.4 Replication analysis with GEO BRCA data
We performed a replication analysis using an independent DNA methylation data of BRCA
tumor and normal-adjacent tissues from GEO (GSE69914) (Teschendorff et al., 2016a).
The original GEO BRCA DNA methylation data have methylation measures on 385,184
CpG sites from 42 tumor and normal-adjacent pairs, 50 normal/benign controls from age-
matched cancer-free women and 263 tumor tissues from independent breast cancer patients.
We followed the same quality control steps as for the TCGA BRCA data and kept the same
sets of CpG sites as in the TCGA BRCA data for comparison purpose. We ended up with
326,105 CpG sites from 42 tumor and normal-adjacent pairs.
We compared results from the TCGA BRCA data and the GEO BRCA data and found
that 94.7, 94.4, 87.6, 87.2, 86.3, 80.2 and 95.4% of sites in the DMRs identified in the GEO
BRCA tumor versus normal-adjacent comparison were also identified in the TCGA BRCA
tumor versus normal-adjacent comparison by the new method, paired t-test, DMRcate,
Probe Lasso, Wilcoxon signed-rank test, Pitman-Morgan test and KS test, respectively. We
plotted two example overlapping DMRs (Figure 2.4). The first DMR is hypo-methylated
and ranks #1 among all DMRs identified by the new method in both BRCA data sets.
The second DMR is hyper-methylated and ranks #5 among all DMRs identified by the new
method in the TCGA BRCA data and ranks #13 among all DMRs identified by the new
method in the GEO BRCA data.
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Figure 2.4: Two examples of overlapping DMRs among all DMRs identified by the new method
in both the TCGA and the GEO BRCA data from the tumor versus normal-adjacent comparison.
Plotted are the combined site-level signal scores in the DMRs before and after smoothing for the
TCGA BRCA data (circles, solid curves) and the GEO BRCA data (crosses, dashed curves). Vertical
lines define boundaries of DMRs, and horizontal lines define the threshold k that defines a candidate
region.
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Although sites in DMRs identified using the Pitman-Morgan test have the smallest
replication rate (80.2%) as expected, it is still large enough to conclude that DMRs detected
using variance signals are reproducible. Sites in DMRs identified in the two BRCA data sets
using the new method, paired t-test and KS test can be almost perfectly reproduced with
replication rates 94.7, 94.4 and 95.4%, respectively. This agrees with the general believe
that DMR findings might be more reliable than DML findings, supporting the meaning of
detecting DMRs.
Details of the DMRs identified by the new method and the six comparison methods in the
GEO BRCA data are summarized in Table 2.3. We found that 67.5, 7.7, 10.7 and 86.8% of
sites in the DMRs that were identified by the mean-only methods: paired t-test, DMRcate,
Probe Lasso and Wilcoxon signed-rank test were also identified by the new method, 83.0%
of sites in the DMRs identified by the Pitman-Morgan test were also identified by the new
method and 81.9% of sites in the DMRs identified by KS test were also identified by the
new method. Similarly as in the TCGA BRCA and KIRC data, DMRs identified uniquely
by the paired t-test or Pitman-Morgan test were all defined by the new method but did not
reach significance.
We similarly plotted the top #1 and #2 ranked DMRs in the GEO BRCA tumor versus
normal-adjacent comparison (Supplementary Figure A.4) and further investigated genes in
the top 10 DMRs (Supplementary Table A.3), where similar patterns were observed as in
the TCGA BRCA and KIRC data.
2.5.5 Identification of epigenetic field defects in the GEO BRCA data
Teschendorff et al. (Teschendorff et al., 2016a) showed in their recent paper that the identi-
fication of early epigenetic alterations, commonly known as epigenetic field defects, through
comparing DNA methylation measures of normal-adjacent tissues from breast cancer pa-
tients to normal tissues from age-matched cancer-free women is meaningful in the study
of breast cancer development, and the differences are expected to be larger in compar-
isons between tumor and normal-adjacent tissues, and between tumor and normal tissues
from cancer-free women. The original paper investigated the epigenetic field defects on the
CpG site level. Here, we further investigated epigenetic field defects on the region level.
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We kept the same 326,105 CpG sites as in the GEO BRCA tumor versus normal-adjacent
comparison.
We first examined the distributions of the estimated genome-wide site-level scaling pa-
rameter λi from the three comparisons (Supplementary Figure A.5) (1) normal-adjacent
tissues from breast cancer patients versus normal tissues from age-matched cancer-free
women, (2) tumor tissues versus matched normal-adjacent tissues from breast cancer pa-
tients and (3) tumor tissues from breast cancer patients versus normal tissues from age-
matched cancer-free women in the GEO BRCA data.
As defined in Equation 2.2, the site-level scaling parameter λi reflects the relative
strength of the mean and variance signals at CpG site i. CpG sites with λi = 0 do not have
any variance signals, CpG sites with λi = 1 do not have any mean signals and CpG sites
with 0 < λi < 1 have both mean and variance signals, within which sites with λi > 0.5 have
stronger variance signals than mean signals. Supplementary Figure A.5 suggests that in the
normal-adjacent versus normal comparison, there are much fewer sites with both mean and
variance signals and a lot more sites with only variance signals comparing with the other
two comparisons. The parameter λ that reflects the genome-wide relative signal strength
is also the largest in the normal-adjacent versus normal comparison. This suggests that
differential variation exists earlier in disease progression, which is consistent with the find-
ings by Teschendorff et al. (Teschendorff et al., 2016a) that there is increased variability in
DNA methylation within the normal-adjacent tissues comparing with normal breast tissue
from age-matched cancer-free women.
We then examined the identified DMRs in the three comparisons using the GEO BRCA
data (1) normal-adjacent versus normal, (2) tumor versus normal-adjacent and (3) tumor
versus normal. In the normal-adjacent versus normal comparison that aims for epigenetic
field defects, the new method identified two DMRs (Supplementary Figure A.6 shows the
mean and variance signals of the two DMRs), both hyper-methylated, while all the six
comparison methods identified none. Importantly, all 58 CpG sites covered by these two
DMRs of epigenetic field defects are also in the DMRs identified in the tumor versus normal-
adjacent, and tumor versus normal comparisons (results summarized in Supplementary
Table A.4 and Supplementary Figure A.7). These 58 sites cover two genes, NKX6-2 and
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Heat map of field defects



























































































































































































































Figure 2.5: (A) The epigenetic field defects, i.e. the two DMRs identified in the GEO BRCA normal-
adjacent versus normal comparison (crosses, dotted curves) together with the overlapping DMRs
identified in the GEO BRCA tumor versus normal-adjacent comparison (circles, dashed curves),
and the GEO BRCA tumor versus normal comparison (triangles, solid curves). Vertical lines define
boundaries of DMRs, and horizontal lines define the threshold k that defines a candidate region. (B)
Heat maps of the original DNA methylation measures of the sites from the epigenetic field defects,
i.e. the two DMRs identified in the GEO BRCA normal-adjacent versus normal comparison. Green
is for 50 normal tissues from age-matched cancer-free women. Blue is for 42 normal-adjacent tissues,
and red is for 42 tumor tissues. (C) Two CpG sites selected of the 58 sites from the epigenetic field
defects, i.e. the two DMRs. Plotted are the original DNA methylation measures of normal tissues
from 50 age-matched cancer-free women (crosses), and normal-adjacent tissues (circles) and tumor
tissues (triangles) from 42 BRCA patients. The three horizontal lines represent mean methylation
levels of the three groups. λi(NN) is the site-level scaling parameter from the normal-adjacent versus
normal comparison, and λi(TN) is that from the tumor versus normal-adjacent comparison. The
three outlier samples were marked using solid circles (normal-adjacent tissues) and solid triangles
(matching tumor tissues).
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CCND2. Both were previously reported to be differentially methylated in breast cancer
(Fackler et al., 2011; Sharma et al., 2007; Virmani et al., 2003). Moreover, for the two DMRs
of epigenetic field defects, the #1 ranked DMR ranks #18 in the tumor versus normal-
adjacent comparison and ranks #11 in the tumor versus normal comparison (Figure 2.5A);
the #2 ranked DMR ranks #2 in the other two comparisons (Figure 2.5A). Sites in these two
DMRs have larger combined signal scores in the tumor versus normal-adjacent, and tumor
versus normal comparisons than those from the normal-adjacent versus normal comparison.
This suggests that there exists epigenetic field defects earlier in disease progression, and the
epigenetic field defects are enriched in the progression to breast cancer, confirming what
is observed before on the CpG site level (Teschendorff et al., 2016a) using region-based
method.
To further investigate whether the epigenetic field defects identified in the normal-
adjacent versus normal comparison are because of a few outlier samples as Teschendorff
et al. (Teschendorff et al., 2016b) noticed, and whether the notable DNA methylation al-
terations at the identified CpG sites are real but not technical artifact, we plotted two heat
maps of sites in the two DMRs of epigenetic field defects (Figure 2.5B). It is clear that there
is little variation in DNA methylation measures of normal tissues, and increased variation
in those of normal-adjacent tissues because of three to five samples and much increased
variability in those of tumor tissues. We further selected two sites with large variance sig-
nals (λi = 0.72 and 0.76) out of the 58 sites covered by the two DMRs and plotted their
methylation measures (Figure 2.5C). It is clear that at these two sites, there is little vari-
ation in DNA methylation measures of normal tissues and increased variation in those of
normal-adjacent tissues, mainly because of to three to five outlier samples, and there is no
mean difference in DNA methylation measures between the normal and normal-adjacent
tissues (Figure 2.5C). We also notice that the three outlier samples exhibit greater methy-
lation deviations in tumor tissues than in normal-adjacent tissues, indicating an enriched
methylation alteration with cancer progression (Figure 2.5C). We would like to emphasize
that the two DMRs of epigenetic field defects in the normal-adjacent versus normal compar-
ison were only identified by the new DMR detection method that uses mean and variance
combined signals but were missed by all the other six comparison methods, which suggests
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the great power achieved by the new DMR detection method.
2.6 Discussion
Here, we proposed a new DMR detection method that uses combined signals from differ-
ential methylation and DV. Simulation studies showed the correct type I error and the
much improved power of the new method when true DMRs have sites with both mean and
variance signals. Applications to the TCGA BRCA, TCGA KIRC and GEO BRCA DNA
methylation data showed that the majority of genes in the uniquely identified DMRs by the
new method were previously reported to be associated with cancers. Replication analysis
results using two independent BRCA data sets suggest that DMRs detected with variance
signals are reproducible.
Importantly, further application to the DNA methylation data of GEO BRCA normal-
adjacent tissues from breast cancer patients and normal tissues from age-matched cancer-
free women identified epigenetic field defects in two DMRs only by the new method, while
the comparison mean-only and variance-only methods identified none. These two DMRs
were also identified, and the methylation alterations were enriched in the comparisons of
tumor versus normal-adjacent tissues and tumor versus normal tissues. The identified
epigenetic field defects in these two DMRs could potentially be marks for breast cancer
early detection with future investigations. Owing to the fact that the identified early DNA
methylation alterations in breast cancer are characterized by increased variability because
of a few ‘outlier’ samples when both mean and variance signals are weak and mean-only
method and variance-only method could detect no differences, existing methods that focus
on mean signals only or adapted methods that focus on variance signals only will be seriously
underpowered. This shows the importance of using mean and variance combined signal,
especially in identifying epigenetic field defects.
Although we did not consider correcting for differences in variances between batches,
in the context of the data presented in this article, this is not an issue for the following
two reasons (1) many previous studies (Teschendorff et al., 2016a; Teschendorff and Wid-
schwendter, 2012; Teschendorff et al., 2012) have unequivocally demonstrated that most of
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the differentially variable loci (DVL) are not batch or technical effects; (2) DVL are indeed
generally characterized by fairly large changes in DNA methylation (>30% if not more) af-
fecting a small number of samples, whereas batch effects generally involve smaller (10-15%)
changes in DNA methylation, which affect most if not all the samples within a batch.
Furthermore, we did not adjust for cell-type composition in our analysis as Teschendorff
et al. (Teschendorff et al., 2016a) have clearly demonstrated that DVL are not driven by
changes in cell-type composition: (1) the DVL do not map to markers of adipose cells or
immune cells, which are two main types of cell contaminants in breast tissue, (2) changes
in cell-type composition between two phenotypes (e.g. normal versus normal-adjacent, or
normal versus tumor) only involve relatively smaller changes in DNA methylation (10-15%).
In contrast, DVL generally involve much larger changes in DNA methylation (>30%), which
only affect a smaller number of samples. Their previous study also demonstrated that (3)
the same DVL were found after adjustment for changes in cell-type composition. Put
together, it is clear that most of the DVL are unrelated to cell-type composition changes,
and that they instead mark pre-cancerous cells on route to becoming cancerous.
One thing we noticed in using methylation variance signals is, when methylation M -
values are used, the mean and variance signals may not be completely separated. We have
conducted some simulation studies in our previous work and found that if only mean signals
are designed in the M -values, there will be both mean and variance signals in β-values after
the transformation (Sun et al., 2017).
In summary, we proposed a new DMR detection method that uses mean and variance
combined signals. Although we applied the new method to multiple cancer data sets, the
method can be applied to other complex diseases. We focused on methylation array data in
this work, but the new method is readily applied to sequencing data with sequencing data
being preprocessed to methylation proportions.
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Chapter 3
Detection of Epigenetic Field
Defects Using a Weighted
Epigenetic Distance-Based Method
3.1 Introduction
Identifying molecular alterations that happen early in carcinogenesis, known as field defects,
is important for early cancer detection. One common approach is to compare normal tissue
of healthy individuals to normal tissue adjacent to tumor (normal-adjacent tissue) of cancer
patients as a surrogate of pre-cancer tissue that are difficult to collect. There have been
studies in identifying epigenetic field defects (Katsurano et al., 2012; Bernstein et al., 2013;
Teschendorff et al., 2016a,b), notably early DNA methylation alterations. DNA methylation
is an epigenetic modification that has been shown to be crucial in gene expression (Baylin
et al., 2001; Fahrner et al., 2002; Jones, 2012; Phillips, 2008) and cancers (Das and Singal,
2004; Ehrlich, 2002; Esteller and Herman, 2002; Kulis and Esteller, 2010). There are mainly
two types of aberrant DNA methylation in cancers, local hyper-methylation in promoter-
related CpGs that leads to the silencing of down-stream tumor suppressor genes (Koukoura
et al., 2014; Baylin, 2005; Curradi et al., 2002; Herman and Baylin, 2003; Robertson, 2005),
and global hypo-methylation that leads to chromosome instability (Robertson, 2005; Eden
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et al., 2003; Feinberg and Tycko, 2004; Jaenisch and Bird, 2003). Studies have successfully
identified epigenetic field defects in breast cancer by comparing normal-adjacent tissue of
breast cancer patients to normal tissue from healthy individuals. Teschendorff et al. iden-
tified epigenetic field defects in breast cancer based on differential variability (DV), i.e.
variance signals in DNA methylation (Teschendorff et al., 2016a), using methylation site-
level analyses. Our previous work (Wang et al., 2017) identified epigenetic field defects in
breast cancer based on both differential methylation (DM), i.e. mean signals, and DV, using
methylation region-level analyses. In both studies, epigenetic field defects were found to be
mainly driven by increased variation in methylation due to several outlier normal-adjacent
tissue samples.
Due to the fact that CpG site-level signals for epigenetic field defects may be very small,
existing methods based on differences (DM or DV or both) on CpG site-level may not have
good power. Standard epigenome-wide association studies (EWAS) that focus on mean
signals (EWAS-DM) perform CpG site-level tests to identify differentially methylated CpGs
between two experimental groups using standard tests such as a t-test, a regression-based
test or its regularized versions (Tusher et al., 2001; Smyth, 2004; Wettenhall and Smyth,
2004), or a non-parametric Wilcoxon rank sum test (Wilcoxon, 1945). EWAS that focus on
variance signals (EWAS-DV) perform CpG site-level tests to identify differential variation
CpGs between two experimental groups using standard tests such as the F -test (Hansen
et al., 2011b; Ho et al., 2008), the Bartlett’s test or its regularized version (Teschendorff
et al., 2016a,b), or an empirical Bayes extension of the Levene’s test (Phipson and Oshlack,
2014). The F -test and Bartlett’s test are sensitive to departures from normality which
is usually the case for methylation data, while the Levene’s test is more robust to non-
normality. On the other hand, distance-based methods that characterize (dis)similarity
between pairwise samples across a gene, a genetic region, a pathway or an entire genome
have been proven to be powerful in genetic and gene expression studies (Zapala and Schork,
2006; Wessel and Schork, 2006; McArdle and Anderson, 2001; Anderson, 2001; Han and
Pan, 2010). While standard EWAS perform CpG site-level tests with stringent multiple
comparisons adjustment, in a gene or a genetic region level, the common practice using non-
distance-based methods is to select the minimum P -value out of all CpGs in that region.
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These methods will not be powerful when site-level effects are very small. Alternatively,
the distance-based methods accumulate any CpG site-level signals from a gene or a genetic
region via the (dis)similarity matrix thus boost the overall association power, making them
the ideal methods for detection of epigenetic field defects.
Here, we developed a weighted epigenetic distance-based method to identify epigenetic
field defects at gene or genetic-region levels using both DM and DV signals. CpG site-level
weights were incorporated in the calculation of (dis)similarity matrix to further boost sig-
nals and reduce noises. Specifically, we used original DNA methylation measures to examine
DM and centered quadratic methylation measures to examine DV and considered site-level
weights based on strengths of site-level DM and DV signals. Simulation studies showed
much improved performance of the proposed weighted epigenetic distance-based method
over several comparison methods including non-weighted versions and methods that use
either DM or DV signals as well as standard EWAS methods. We further demonstrated the
performance of the proposed method through an application to the 450K DNA methylation
data of normal-adjacent tissue of breast invasive carcinoma (BRCA) patients and normal
tissue from independent age-matched cancer-free women from Gene Expression Omnibus
(GEO). The proposed method that accumulates weighted DM and DV signals identified
genes with epigenetic field defects that were missed by standard EWAS methods and non-
weighted distance-based methods. Many of these epigenetic field defects were previously
reported to be associated with breast cancer. Further examination confirmed their enrich-
ment in the progression to breast cancer and replicated some of these identified epigenetic
field defects.
3.2 Materials and methods
Case-control designs using normal tissue from healthy individuals (Y = 0) and normal tis-
sue adjacent to tumor from cancer patients (Y = 1) as a surrogate of pre-cancer tissue are
widely used to identify epigenetic field defects in cancers. We therefore focused on case-
control designs and illustrated and applied the proposed weighted epigenetic distance-based
method on gene level. However, the proposed method can be easily adapted to other types
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of design and on genetic region or genome levels. There are three steps in the proposed
distance-based method: (i) to define gene-level weighted epigenetic distance matrix; (ii) to
calculate pseudo-F statistic and (iii) to assess statistical significance using permutations.
Step 1: Define gene-level weighted epigenetic distance matrix
Define epigenetic distance matrix. For each gene, let Xm be a 2N × n matrix with orig-
inal DNA methylation measures for N cases and N controls of n CpG sites in a gene,
where element xmij harbors DNA methylation measure of the j-th CpG site, j = 1, ..., n
in the gene, for the i-th subject, i = 1, ..., N . This Xm matrix will be used to examine
differential methylation (DM) capturing methylation mean signals. Let Xv be a 2N × n
pseudo-data matrix of variability score capturing methylation variance signals, which will
be used to examine differential variability (DV). The element xvij = (x
m
ij − x̄mj )2 harbors







ij is the mean methylation measure of the j-th CpG site across N
cases and N controls separately. The quadratic terms are centered to better capture vari-
ance signals. By using Xmv = [Xm,Xv], a 2N × 2n matrix, we will be able to capture both
methylation mean and methylation variance signals of the n CpG sites. Before constructing
the epigenetic distance between any pair of subjects, we performed normalization on each
column of Xmv such that each column has mean zero and unit standard deviation.
We define the 2N × 2N epigenetic distance matrix DDM−DV with element dDM−DVst


















Incorporate CpG site-level weights into epigenetic distance matrix. We construct CpG site-
level weights aiming to up-weight signal CpGs (mean or variance) and to down-weight noise
CpGs in calculating distances between pairs of subjects. Therefore, we define weights for
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where pmj and p
v
j are the P -values from the two-sided two-sample t-test testing if the mean
methylation measures are the same between cases and controls and from the one-sided
Levene’s test testing if the variance of the methylation measures in cases is greater than









The corresponding 2N × 2N weighted epigenetic distance matrix Dw−DM−DV with
element dw−DM−DVst that captures weighted dissimilarities between individuals s and t,

















Step 2: Calculate pseudo-F statistic
We apply distance-based regression originally developed in the field of ecology (McArdle
and Anderson, 2001; Anderson, 2001) to test if DNA methylation measures in a gene is
associated with the case-control status. Specifically, for each gene, we calculate a pseudo-F





where H = Y(YTY)−1YT is a 2N × 2N projection matrix, Y is a 2N × 1 vector with
case (Y = 1) and control (Y = 0) status, G = (I − 12N 11
T )A(I − 12N 11
T ) is the Gowers






, 1 is a 2N -dimensional column vector
with elements 1, and I is a 2N × 2N identity matrix. The pseudo-F statistic is used to
evaluate the association between epigenetic distances of a gene with n CpG sites and the
case/control status.
Step 3: Assess statistical significance using permutations
To access significance of all G genes tested, we use permutation procedures, where we ran-
domly shuffle cases (Y = 1) and controls (Y = 0) and repeat Steps 1-2 on the permuted
data. In order to have more granular P -values, we pool pseudo-F statistics of all G genes
from all permutations, as well as those from the observed data, to compute the empirical
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P -value (Friedman et al., 2001). We repeat the permutation procedure 999 times, and







g′,perm ≥ Fw-DM-DVg )}
G× (1 + 999)
(3.5)
In the real data application, we haveG=19,271 genes, which helps to have high resolution
gene-level empirical P -values.
To investigate if genes with different sizes, i.e., number of CpGs, will have different
distributions for pseudo-F statistics under the null hypothesis, we conducted simulation
studies to compare the type I error rates when the P -value for each gene is calculated based
on pooled pseudo-F statistics of all G genes across all permutations (Supplementary Section
B.1.1).
3.2.1 Comparison methods
We compare the performance of the proposed method Dw−DM−DV that considers site-level
weights for mean and variance signals to that of several comparison methods, including
the weighted distance-based methods that consider mean signals only Dw−DM or variance
signals only Dw−DV , and distance-based methods without weights that consider both mean
and variance signals DDM−DV , mean signals only DDM , variance signals only DDV , and
standard EWAS methods on each CpG site with multiple comparisons adjustment of number
of CpGs in a gene based on mean signals EWASDM or variance signals EWASDV .
3.2.2 Simulation study
We conducted simulation studies to evaluate type I error rate and power of the proposed
method Dw−DM−DV and those of the comparison methods described above. Type I error
rate is defined as the proportion of simulations with any significant genes when the data
is generated under the null hypothesis of no genes are associated with case-control status.
Power is defined as the proportion of simulations with any significant genes when the data
is generated under the alternative hypothesis.
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3.2.3 Simulation setup
We simulated methylation measures X of cases (Y = 1) and controls (Y = 0) at every CpG
site in a gene from beta distributions:
X|Y = 0 ∼ Beta(a0, b0)
X|Y = 1 ∼ Beta(a1, b1)
where shape parameters a0 and b0 for samples in the control group were chosen based on
estimates from the 50 normal tissue samples from cancer-free women in the GEO BRCA
data (GSE69914), and shape parameters a1 and b1 for samples in the case group were
chosen based on estimates from the 42 normal-adjacent tissues in the GEO BRCA data.
More specifically, the average of the methylation means and standard deviations (SDs) of
all CpG sites with gene information for the 50 normal tissue samples is 0.47 and 0.05,
respectively. Therefore, we set a0 = 46.36 and b0 = 52.28 for noise CpGs such that the
corresponding mean and SD of the beta distribution are 0.47 and 0.05, respectively. We
generated methylation measures for 40 cases and 40 controls to mimic the size of the GEO
BRCA study. We set a1 = a0 and b1 = b0 for all CpG sites in case and control groups to
evaluate type I error rates. For power scenarios, we considered scenarios when signal CpGs
have different mean or variance signals through varying shape parameters a1 and b1. We
conducted 1,000 simulations in each simulation setting.
3.2.3.1 Simulation settings with one gene
We first considered one gene with different number of CpGs with different signal-to-noise
ratios of the CpGs. That is, the ratio between number of signal CpGs and number of noise
CpGs in this gene ranges from 1:0, 1:24, 1:49, 3:47, to 5:45. We considered scenarios when
signal CpGs have different mean or variance signals by varying shape parameters a1 and b1
such that the mean differences in methylation measures between cases and controls are 0.02,
0.04 0.06, 0.08 and 0.1, and the ratios of SDs for cases and controls are 1.25, 1.50, 1.75, 2,
2.25 and 2.50, respectively. The values of a1, b1 in those scenarios and the corresponding
effect sizes are summarized in the Supplementary Table B.2. We consider a gene to be
significant at the 0.05 significance level.
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3.2.3.2 Simulation settings with 10 genes
We then considered 10 genes with one gene having signals when there are 25 CpGs in each
of the 10 genes. In the signal gene, we set one CpG to have mean or/and variance signals
with different effect sizes. Here we test for the global null and consider a simulation study
to be significant if any gene is significant after Bonferroni adjustment for testing 10 genes.
The empirical P -value for each gene is calculated using formula 3.5, where G = 10.
3.2.3.3 Simulation settings with outliers
Since epigenetic field defects are often characterized by increased variation in DNA methy-
lation due to a few outlier normal-adjacent tissue samples (Teschendorff et al., 2016a; Wang
et al., 2017), we considered simulation scenarios with outlier samples. Here, we only con-
sidered one gene with 50 CpGs for illustration purposes. We considered two signal-to-noise
ratios in this gene to be either 5:45 or 10:40. We set 10%, 15% or 20% of cases to be out-
lier samples with DNA methylation alterations at some signal CpGs, while the rest cases
have the same methylation measures as controls at those signal CpGs when different out-
lier samples could have DNA methylation alterations at different signal CpGs. For each
signal CpG, we generated methylation measures X for cases from a mixture distribution
X = (1 − Z)X1 + ZX2, and methylation measures for controls from X1 ∼ Beta(a0, b0).
Specifically, at each signal CpG, we randomly assigned 40 cases to be either outlier samples
(Z = 1) or non-outlier samples (Z = 0) by Z ∼ Bernoulli(p), where p is the probability
of any case being an outlier sample. We then generated methylation measures of outlier
samples from X2 ∼ Beta(a2, b2) and non-outlier samples from X1 ∼ Beta(a0, b0).
3.2.3.4 Simulation settings with one gene considering correlations among CpGs
Since neighboring CpGs are known to be correlated, we considered simulation scenarios
that assume an AR(1) correlation among CpGs in a gene with a correlation coefficient 0.5.
The detailed information for simulation setup for this scenario is summarized in the Sup-
plementary File (Section B.1.3 Simulation settings with one gene considering correlations
among CpGs).
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Table 3.1: Type I error rates
Methods
1 gene 10 genesa
1 CpGb 25 CpGs 50 CpGs 25 CpGs
Dw−DM−DV 0.044 0.044 0.037 0.050
Dw−DM 0.046 0.032 0.048 0.053
Dw−DV 0.048 0.056 0.048 0.049
DDM−DV 0.044 0.052 0.045 0.054
DDM 0.046 0.043 0.041 0.057
DDV 0.044 0.052 0.054 0.045
EWASDM 0.046 0.030 0.039 0.050
EWASDV 0.044 0.047 0.040 0.037
aType I error rates after Bonferroni adjustment for 10 genes.
bNumber of CpG sites in a gene.
3.3 Results
3.3.1 Simulation results
3.3.1.1 Type I error rate
Type I error rates are well controlled at the 0.05 significance level in settings with one gene
and 10 genes after Bonferroni adjustment for multiple comparisons (Table 3.1), respectively.
3.3.1.2 Power for simulation settings with one gene
Power results for simulation settings with one gene are summarized in Figure 3.1. When
there are only mean signals at signal CpGs, Dw−DV , DDV and EWASDV that consider
variance signals only do not have any power as expected. When there is only one CpG in
the gene, the non-weighted distance-based methods are the same as the weighted versions,
as well as the EWAS method as expected. When there is one signal CpG and increasing
number of noise CpGs in the gene, power of DDM decreases drastically while power of the
weighted version Dw−DM are well maintained. This suggests that incorporating weights to
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Figure 3.1: Power results for simulation settings with one gene. The signal gene has one signal
CpG and increasing number of total CpGs, i.e., decreasing signal-to-noise ratios from 1:0, 1:24 to
1:49 (panel A for mean signals only, panel B for variance signals only), or with a fixed total number
of CpGs 50 and increasing signal-to-noise ratios from 1:49, 3:47, to 5:45 (panel C for mean signals
only, panel D for variance signals only).
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CpGs indeed helps to up-weight signal CpGs and down-weight noise CpGs in constructing
the distance matrix, thus improves the performance. When the size of a gene, i.e., number
of CpGs in a gene, is fixed, among which when the number of signal CpGs increases, power
of Dw−DM increases much slower than that of DDM while Dw−DM always has greater power
than that of DDM . This implies that adding weights is most effective when a small percent
of CpGs in a gene are signals. Similar power patterns are observed between weighted
and non-weighted versions of the distance-based methods that consider both mean and
variance signals, Dw−DM−DV and DDM−DV . We also notice that Dw−DM−DV is slightly
less powerful than Dw−DM because the overall mean signals are diluted by the inclusion of
pseudo-sites for variance when there are only mean signals in the data. Moreover, Dw−DM
slightly outperform EWASDM when there are several signal CpGs. This is because the
distance-based method has the advantage to accumulate weak signals and thus boost the
overall power.
Similar power patterns are observed when signal CpGs are set to have variance signals
only. Dw−DM , DDM and EWASDM that consider mean signals only do not have any
power, and the weighted distance-based methods outperform the non-weighted versions in
the presence of noise CpGs, and Dw−DV performs better than Dw−DM−DV , and Dw−DV
outperforms EWASDV when there are several signal CpGs.
3.3.1.3 Power for simulation settings with 10 genes
Power results for simulation settings with 10 genes are summarized in Figure 3.2. When
signal CpGs have either mean or variance signals, we observed similar patterns as in the
simulation settings with one gene. When signal CpGs have non-negligible mean signals and
variance signals ranging from weak to strong, Dw−DM−DV performs the best when variance
signals are also weak to moderate as expected. This confirms that the potential area of
usage for distance-based methods to be most effective is when there are weak signals that
could be accumulated to boost the study power. When there are very strong signals at some
sites, any methods will perform well. One observation that we need to point out is, powers of
Dw−DM , DDM and EWASDM that only consider mean signals actually decrease as variance
signals increase when mean signals exist. This is due to the fact that we worked on the
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Figure 3.2: Power results for simulation settings with 10 genes. We set each gene to have 25 CpGs
and only one gene to have signals. The signal gene has 1 signal CpG and 24 noise CpGs, with signal
CpG having mean signal only (panel A), variance signal only (panel B), and mean and variance
signals with different sizes of mean signals (panels C and D)
standardized data in Xmv = [Xm,Xv], and the effect sizes of mean signals (standardized
mean difference) decrease as the effect sizes of variance signals (ratio of standard deviation
for cases and controls) increase after standardization.
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Figure 3.3: Power results for simulation settings with outlier samples. We set to have 10%, 15%
and 20% outlier samples and two different signal-to-noise ratios 5:45 and 10:40
3.3.1.4 Power for simulation settings with outliers
Power results for simulation settings with outlier samples are summarized in Figure 3.3.
We observe that power of all methods increases as the signal-to-noise ratio increases and
as the proportion of outlier samples increases as expected, and distance-based methods
outperform non-distance-based methods while EWASDM and EWASDV have very little
power when there are only 10% outlier samples. Among distance-based methods, Dw−DM
and DDM that consider mean signals only have lower power compare to other methods as
the mean signals introduced by a few outlier samples are usually too weak to be detected
by methods that consider mean signals only. On the other hand, DDM−DV that considers
both mean and variance signals outperforms methods that consider variance signals only,
DDV .The two weighted distance-based methods Dw−DM−DV and Dw−DV are among the
best performed methods consistently. This implies the superiority of Dw−DM−DV in the
presence of weak signals in both DM and DV.
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3.3.1.5 Power for simulation settings with one gene considering correlations
among CpGs
The type I error rates under this scenario are summarized in Supplementary Table B.3.
The power results are summarized in Supplementary Figure B.1. We note that the power
patterns are very similar to those observed in simulations ignoring correlations among CpG
sites. This implies that the correlations among neighboring CpGs do not have much impact
on the performance of the proposed distance-based methods.
3.3.2 Real data application
We applied the proposed method Dw−DM−DV and all the comparison methods to two
GEO 450K DNA methylation data of breast invasive carcinoma (BRCA) (GSE69914 and
GSE67919). As we have demonstrated the superior power of Dw−DM−DV over other
distance-based methods in the simulation studies, we focused on Dw−DM−DV in the real
data application and compared its performance to that of the EWAS method in the main
text and included results using all other comparison distance-based methods in the Sup-
plementary File (Section B.2 Real data application). In order for the two EWAS methods,
EWASDM and EWASDV , to have a fair comparison with Dw−DM−DV , we first adjusted
multiple comparisons for the number of CpGs in a gene by multiplying the site-level P -
values based on DM and DV with the number of CpGs in the gene, and then selected the
minimum adjusted DM and DV P -value across all P -values in the gene as the gene-level
P -value. We refer to this method as EWASmin−P .
3.3.3 Discovery analysis using the GEO BRCA data
We applied the proposed method Dw−DM−DV and the comparison methods to the GEO
450K DNA methylation data of normal-adjacent tissue of breast invasive carcinoma (BRCA)
patients and normal tissue from independent age-matched cancer-free women (GSE69914).
In the original GEO BRCA data, there are DNA methylation measures on 485,512 CpGs
for 42 tumor and normal-adjacent pairs from breast cancer patients, 50 normal tissue of
independent age-matched cancer-free women and 263 additional tumor tissue of independent
breast cancer patients. We conducted standard quality control steps where we removed
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Figure 3.4: Manhattan plots with results from Dw−DM−DV and EWASmin−P . The solid horizontal
line is the 0.0005 gene-level P -value threshold. The dashed horizontal line is the Bonferroni adjusted
0.05 significance level (0.05/19 271 genes = 0.0000026 adjusted gene-level P -value threshold). Genes
annotated with stars are those identified by both methods at the 0.0005 gene-level P -value threshold.
CpGs on sex chromosomes and those contain either a SNP at the CpG interrogation or
at the single nucleotide extension (SBE) based on UCSC dbSNP table version 147 using
the R package ‘IlluminaHumanMethylation450kanno.ilmn12.hg19’ (Hansen, 2015). We also
required at least 95% CpG coverage per sample and 70% sample coverage per CpG, and only
kept CpGs with gene annotations. We ended up with 344,947 CpGs, covering 19,271 genes,
from 42 normal-adjacent tissues, 50 normal tissues and 263 independent tumor tissues.
Since Bonferroni adjustment for multiple comparisons of the 19,271 genes is too con-
servative, especially with the small sample size in the GEO BRCA dataset, we used a less
stringent threshold 0.0005 on empirical gene-level P -values obtained from the permutation
procedure (Figure 3.4). Our main purpose is to demonstrate the superior performance of
the proposed method Dw−DM−DV over several comparison methods, especially the EWAS
methods. Results using Dw−DM−DV and EWASmin−P comparing 42 normal-adjacent tis-
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sues to 50 normal tissues are shown in the Manhattan plots in Figure 3.4. At the 0.0005
threshold for gene-level P -values, Dw−DM−DV identified 21 genes (Table 3.2), of which 18
were previously reported to be associated with breast cancer; EWASmin−P identified 14
genes (Table 3.3), of which 9 were previously reported to be associated with breast cancer.
There are 7 overlapping genes, TMC4, NAA35, THY1, CXCL6, KDM5A, FKBP4, and
TMEM200B that were identified by both methods. Except for the PLS1 gene, the 7 genes
uniquely identified by EWASmin−P all rank very high in Dw−DM−DV results out of the
19,271 genes (Table 3.3). Except for the CFTR gene, the 14 genes uniquely identified by
Dw−DM−DV also all rank very high in EWASmin−P results. This suggests an overall good
consistency between results of Dw−DM−DV and EWASmin−P . At the same 0.0005 gene-
level P -value threshold, other comparison methods Dw−DM , Dw−DV , DDM−DV , DDM and
DDV identified 11, 9, 2, 6 and 4 genes, of which 6, 7, 1, 3 and 1 genes were also identified
by the proposed Dw−DM−DV (Supplementary Tables B.4-B.8), respectively.
We further examined the 14 and 7 genes uniquely identified by Dw−DM−DV and EWASmin−P ,
respectively. We plotted heatmaps of the original DNA methylation measures of CpG sites
on these genes for the 50 normal tissues, 42 normal-adjacent tissues together with the 42
matched tumor tissues (Supplementary Figures B.2 and B.3). In general, the 14 genes
uniquely identified by Dw−DM−DV are those with multiple CpGs of weak signals, i.e. weak
dense signals. Moreover, some of these weak dense signals were mainly due to a few outlier
normal-adjacent tissue samples, thus were missed by EWASmin−P . The 7 genes uniquely
identified by EWASmin−P are those with just one or two CpGs with very strong signals, i.e.
strong sparse signals. We also plotted heatmaps of 7 genes identified by both Dw−DM−DV
and EWASmin−P (Supplementary Figure B.4).
We then investigated the two genes, CFTR and PLS1, that were uniquely identified by
Dw−DM−DV and EWASmin−P , respectively, but ranked the last using the other method
among all uniquely identified genes. We similarly plotted the heatmap of the original
DNA methylation measures of CpG sites in these two genes (Figure 3.5A). For the CFTR
gene that has 16 CpGs, it is clear that variation in methylation measures increases in the
progression from normal tissues to normal-adjacent tissues and to tumor tissues in multiple
CpGs when there are several samples among the 42 normal-adjacent tissue samples that
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Table 3.2: Twenty one genes identified by Dw−DM−DV at the 0.0005 gene-level P -value
threshold using the GEO BRCA Data
Rank Gene # CpG Cancer
Rank in
EWASmin−P
1 TMC4 * 13 Breast Cancer (Krijgsman et al., 2012) 2
2 ZFP57 5 Breast Cancer (Tada et al., 2015) 16
3 DPH3B 5 - 61
4 NAA35 * 7 Breast Cancer (Abu-Asab et al., 2013) 10
5 ANKRD13B 22 Breast Cancer (Jönsson et al., 2010) 25
6 PENK 23 Breast Cancer (Legendre et al., 2015) 37
7 THY1 * 19 Breast Cancer (Lehmann et al., 2011) 13
8 CXCL6 * 7 Breast Cancer (Bièche et al., 2007) 1
9 KDM5A* 2 Breast Cancer (Hou et al., 2012) 4
10 HBA1 7 Breast Cancer (Wolf et al., 2007) 23
11 SPAG6 16 Acute Myeloid Leukemia (Steinbach et al., 2006) 170
12 AQP3 7 Breast Cancer (Cao et al., 2013) 140
13 TRH 16 Breast Cancer (Nicolau et al., 2011) 28
14 SLC7A4 12 Breast Cancer (Xia et al., 2012) 175
15 FKBP4 * 18 Breast Cancer (Yang et al., 2011) 7
16 PRDM5 18 Breast Cancer (Deng and Huang, 2004) 36
17 MMP23B 2 Breast Cancer (Giussani et al., 2015) 80
18 TMEFF1 5 Breast Cancer (Matise et al., 2012) 156
19 PRSS48 7 - 64
20 CFTR 16 Breast Cancer (Zhang et al., 2013b) 1055
21 TMEM200B* 20 Breast Cancer (Stirzaker et al., 2015) 3
*Genes identified by both Dw−DM−DV and EWASmin−P .
are very different from the normal samples. On the other hand, for the PLS1 gene that
also has 16 CpGs, it was identified uniquely by EWASmin−P because of one signal CpG
site cg00137209 (Figure 3.5A), mainly due to the very small variation in the methylation
measures of the normal tissues. We then plotted DNA methylation measures of the top
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Table 3.3: Fourteen genes identified by EWASmin−P at the 0.0005 gene-level P -value thresh-
old using the GEO BRCA Data






1 CXCL6 * 7 Variance Breast Cancer (Bièche et al., 2007) 11
2 TMC4 * 13 Variance Breast Cancer (Krijgsman et al., 2012) 1
3 TMEM200B* 20 Variance Acute Myeloid Leukemia (Rudenko et al., 2016) 41
4 KDM5A* 2 Variance Breast Cancer (Hou et al., 2012) 4
5 NRBP1 12 Variance Breast Cancer (Wei et al., 2015) 110
6 SALL1 44 Variance Breast Cancer (Wolf et al., 2014) 887
7 FKBP4 * 18 Variance Breast Cancer (Yang et al., 2011) 32
8 NOL6 5 Variance - 160
9 PLS1 16 Variance Breast Cancer (Bi et al., 2015) 1069
10 NAA35 * 7 Variance Breast Cancer (Abu-Asab et al., 2013) 6
11 ZNF132 12 Mean Prostate Cancer (Abildgaard et al., 2012) 118
12 STAU2 39 Variance Hepatocellular Carcinoma (Castaneda et al., 2007) 666
13 THY1 * 19 Variance Breast Cancer (Lehmann et al., 2011) 14
14 FAM198B 14 Variance Breast Cancer (Fidalgo et al., 2015) 84
aMean or variance tests with smaller P -value at the most significant CpG in a gene.
*Genes identified by both Dw−DM−DV and EWASmin−P .
4 P -value ranked CpGs, ranked by CpG site-level P -values from both mean and variance
tests each after adjusting for multiple comparisons for the number of CpGs in the CFTR
gene (Figure 3.5B), which clearly shows elevated methylation levels in the progression to
tumor. For the PLS1 gene, we similarly plotted the DNA methylation measures of the top 2
P -value ranked CpGs (Figure 3.5B), where the #1 ranked CpG cg00137209 is the one that
shows strong variance signal due to very small variation in the methylation measures of the
normal tissues, when neither CpGs showed any enrichment in methylation measures in the
progression to tumor. This suggests that genes uniquely identified by EWASmin−P due to
extreme P -values at one or two CpGs may not be reliable, while genes identified uniquely
by Dw−DM−DV are generally characterized by multiple signal CpGs, thus are more reliable.
We also plotted the DNA methylation measures of all CpGs in these two genes CFTR
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Figure 3.5: (A) Heatmaps of DNA methylation measures of CpGs in the CFTR and PLS1 genes.
The CpGs underlined are the top 4 P -value ranked CpGs in the CFTR gene and the top 2 P -value
ranked CpGs in the PLS1 gene. (B) DNA methylation measures of 50 normal tissues, 42 normal-
adjacent tissues and 42 matched tumors of the top 4 P -value ranked CpGs in the CFTR gene and
the top 2 P -value ranked CpGs in the PLS1 gene. Pm and Pv are P -values from CpG site-level
mean and variance tests adjusted for multiple comparisons for the number of CpGs in the gene.
The three horizontal lines represent mean methylation levels of the three groups of normal tissues,
normal-adjacent tissues and matched tumors.
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and PLS1 (Supplementary Figures B.5 and B.6, respectively). It is again clear that almost
half of the CpGs in the CFTR gene have weak mean signals and weak variance signals, thus
missed by EWASmin−P due to stringent multiple comparisons adjustment. In addition,
we plotted the weighted distance matrices of the 50 normal tissues and the 42 normal-
adjacent tissues for the CFTR gene and the PLS1 gene (Supplementary Figure B.7). For
the CFTR gene, we observe little variation in distances among normal samples and increased
variation in distances between several pairs of normal and normal-adjacent samples, while
for the PLS1 gene, we observe no clear pattern. We also plotted the DNA methylation
measures of CpGs in the TMC4 gene (Supplementary Figure B.8) that was identified by
both Dw−DM−DV and EWASmin−P and ranked #1 and #2 in the two methods, respectively.
There are 13 CpGs in the TMC4 gene, 3 CpGs have strong variance signals when two of
the three CpGs also have mean signals. Thus, the TMC4 gene was identified by both
Dw−DM−DV and EWASmin−P .
In our previous work on differentially methylated regions (DMRs) using the same GEO
BRCA data, we identified 2 DMRs of epigenetic field defects using both mean and variance
signals (Wang et al., 2017). The two DMRs cover two genes, NKX62 and CCND2, which
rank #113 and #359 in the Dw−DM−DV results. Further investigation revealed that the
two DMRs only cover part of the two genes. We therefore broke down the two genes into
smaller parts so that there is one part that covers exactly the identified DMR. We then
treated these smaller parts as individual regions and repeated Dw−DM−DV across the whole
genome. The rank of the NKX62 part that matches with the DMR moved up to #90 from
#113 while the other two parts rank #107 and #4855, respectively. The rank of the CCND2
part that matches with the other DMR moved up to #154 from #359 and the other part
ranks #1116. Overall, the 2 DMR-covered genes previously identified as epigenetic field
defects also rank on top in the results of Dw−DM−DV . This suggests that we may combine
DMR detection techniques with distance-based methods to first better define ‘regions of
interest’ using DMR ideas and then assess significance more powerfully with distance-based
methods.
We also investigated the relation between the number of CpGs in a gene and the prob-
ability that the gene is selected, where we binned genes based on their sizes and calculated
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the selection probability of a gene in a bin as the proportion of genes identified out of all
genes in the bin. We plotted the selection probabilities against gene sizes (Supplementary
Figure B.9) and found that the selection probabilities for different versions of the distance-
based methods and EWASmin−P method are not systematically affected by gene sizes.
3.3.4 Validation of the identified epigenetic field defects in the GEO
BRCA data
We further validated the 21 genes of epigenetic field defects identified by Dw−DM−DV
through comparing methylation measures of the 21-gene-covered CpGs between 263 inde-
pendent tumor tissues and 42 normal-adjacent tissues to examine if the methylation levels
at these CpGs exhibit progression to tumor. Specifically, we performed the two-sample
t-test at each of these CpGs and plotted the − log10(P -value) from the two comparisons, 50
normal tissues versus 42 normal-adjacent tissues and 42 normal-adjacent tissues versus 263
tumor tissues (Supplementary Figure B.10). In general, the majority of these CpGs show
more significant signals in the progression from normal tissues to normal-adjacent tissues
to tumors.
3.3.5 Replication analysis using an independent data of normal tissues
As epigenetic field defects identified in one set of normal vs. normal-adjacent comparison
may be driven by a few ‘outlier’ normal-adjacent samples (Teschendorff et al., 2016a,b;
Wang et al., 2017), different epigenetic field defects could be identified in a different set
of normal versus normal-adjacent comparison that are driven by different ‘outlier’ normal-
adjacent samples. Therefore, we propose to conduct a replication analysis that uses the same
normal-adjacent tissue samples but compare to an independent data of normal samples. We
used 450K DNA methylation data of 18 normal tissue of 18 breast reduction mammoplasty
subjects (GSE67919) (Hair et al., 2015). The original data have methylation measures on
485,577 CpG sites. We followed the same quality control steps as for the discovery GEO
BRCA data (GSE69914) and kept the same CpG sites for comparison purposes. We ended
up with 344,947 CpGs, covering 19,271 genes, from 18 normal tissues. We then compared
these normal samples to the same 42 normal-adjacent tissues from the GEO BRCA data in
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a replication analysis.
At the same 0.0005 threshold for gene-level P -values, 7 out of the 21 previously iden-
tified genes with epigenetic field defects in the discovery analysis using the GEO BRCA
data were replicated by Dw−DM−DV . The seven genes are DPH3B, NAA35, ANKRD13B,
CXCL6, FKBP4, PRSS48 and CFTR. We similarly validated these 7 genes by comparing
P -values from the two-sample t-tests comparing the 18 replication normal samples to the 42
GEO BRCA normal-adjacent samples and P -values from the two-sample t-tests comparing
the 42 GEO BRCA normal-adjacent samples to the 263 independent GEO BRCA tumor
samples (Supplementary Figure B.11). All 7 genes, except the NAA35 and FKBP4, exhibit
progression to tumor. More details of the replication analysis results using Dw−DM−DV ,
EWASmin−P and other comparison distance-based methods were summarized in Supple-
mentary File (Section B.2.3 Replication Analysis) and Supplementary Table B.9 and Sup-
plementary Figures B.12-B.14.
To investigate our hypothesis that different epigenetic field defects may be identified
when comparing normal samples to a different set of normal-adjacent samples, we obtained
a new set of BRCA normal-adjacent samples (n = 90) from the Cancer Genome Atlas
(TCGA) project together with their matched tumor samples (n = 90). We plotted DNA
methylation measures of CpGs in the 7 replicated genes of the 18 replication normal samples,
the 50 discovery GEO BRCA normal samples, the 42 discovery GEO BRCA normal-adjacent
samples, the 42 discovery GEO BRCA matched tumor samples, and the 90 TCGA normal-
adjacent samples and the 90 TCGA matched tumor samples. It is clear that methylation
patterns of the TCGA normal-adjacent tissues are very different from that of the discovery
GEO BRCA normal-adjacent tissues in most of these CpGs. This supports our hypothesis
that methylation patterns can be very different in different pre-cancer tissues (using normal-
adjacent tissue as a surrogate) thus different epigenetic field defects may be identified when
normal samples are compared to different sets of pre-cancer tissues.
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3.4 Discussion
In this study, we developed a weighted epigenetic distance-based method Dw−DM−DV that
accumulates both DM (mean) and DV (variance) signals across CpGs in a gene or a genetic
region. One known advantage of distance-based methods is, there is no need to preselect
outcome-associated features, avoiding the potential to mis-screen features with weak sig-
nals. In our proposed weighted epigenetic distance-based method Dw−DM−DV , we used
CpG site-level association strengths as weights for individual CpGs aiming to up-weight
signal CpGs and down-weight noise CpGs. If the feature preselection step could be con-
ducted perfectly, it is equivalent to the case when weight ‘0’ is correctly assigned to noise
CpGs and weight ‘1’ is correctly assigned to signal CpGs. Results from simulation studies
suggest that when the signal-to-noise ratio in a gene decreases, power of non-weighted epi-
genetic distance-based methods decreased drastically, while power of the weighted version
was well maintained. This suggests that incorporating CpG-site-level association strengths
as weights for individual CpGs indeed help to up-weight signal CpGs and down-weight noise
CpGs, thus improve the overall study performance. Simulation results also suggest that the
weighted epigenetic distance-based methods will be most effective when applied to genes or
genetic regions with a small percentage of CpGs having weak signals. This makes the detec-
tion of epigenetic field defects, i.e., early epigenetic alterations that are usually infrequent
across samples and identifiable as outlier samples, the ideal application of the proposed
method Dw−DM−DV . Using the GEO BRCA 450K DNA methylation data, Dw−DM−DV
identified 21 genes with epigenetic field defects, when 7 out of the 21 genes overlap with the
genes identified by EWASmin−P . Majority of the genes uniquely identified by Dw−DM−DV
were previously reported to be associated with breast cancer. Most of the genes uniquely
identified by EWASmin−P also ranked on top in the Dw−DM−DV results except for the
PLS1 gene. However, further investigations suggested that the PLS1 gene may not be a
real epigenetic field defect. On the other hand, most of the genes uniquely identified by
Dw−DM−DV also ranked on top in the EWASmin−P results except for the CFTR gene, in
which the enrichment in the progression to breast cancer was confirmed in further analyses.
This suggests that genes identified by Dw−DM−DV , which are generally characterized by
multiple signal CpGs, are more reliable. It is worth noticing that the 2 DMR-covered genes
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identified in our previous work (Wang et al., 2017) also ranked on top in the Dw−DM−DV
results. We validated the identified epigenetic field defects by showing a progression to tu-
mor in an independent dataset of tumor tissues. We also conducted a replication analysis by
comparing the same set of normal-adjacent tissues to an independent set of normal tissues,
and found that 7 out of the 21 genes of epigenetic field defects identified by Dw−DM−DV in
the discovery analysis were replicated.
In general, distance-based methods have a better performance than that of site-level
EWAS methods when site-level signals are weak. As discussed in our previous work (Wang
et al., 2017) and work of others (Teschendorff et al., 2016a,b), epigenetic field defects are of-
ten characterized by increased variation in DNA methylation measures due to a few outlier
normal-adjacent tissue samples. So the site-level EWAS methods are usually underpow-
ered due to small mean differences as well as stringent multiple comparisons adjustment.
Distance-based methods accumulate weak signals to improve power. Distance-based meth-
ods are flexible and can be applied to a CpG site, a gene, a pathway, or an entire genome. A
closer investigation on what we identified in our previous work (Wang et al., 2017) in DMR
detection and the current work suggests that we may take advantages of the techniques in
DMR detection and combine that with distance-based methods in future works to more
efficiently identify regions of epigenetic field defects.
In summary, we proposed a new weighted distance-based method Dw−DM−DV that
considers both DM and DV in DNA methylation and incorporates site-level association
strengths as weights on individual CpGs to up-weight signal CpGs and down-weight noise
CpGs to further boost the overall study power. The Dw−DM−DV method is especially
powerful in detecting epigenetic field defects when methylation alterations between normal
tissues and normal-adjacent tissues are usually minimum.
CHAPTER 4. A POWERFUL AND FLEXIBLE WEIGHTED DISTANCE-BASED
METHOD INCORPORATING INTERACTIONS BETWEEN DNA METHYLATION
AND ENVIRONMENTAL FACTORS ON HEALTH OUTCOMES 55
Chapter 4
A Powerful and Flexible Weighted
Distance-Based Method
Incorporating Interactions
Between DNA Methylation and
Environmental Factors on Health
Outcomes
4.1 Introduction
DNA methylation has been associated with cancers (Das and Singal, 2004; Ehrlich, 2002;
Esteller and Herman, 2002; Kulis and Esteller, 2010) and a wide range of human diseases
(Feinberg, 2007; Jager et al., 2014; Mill and Petronis, 2007, 2008; Mill et al., 2008; Nestler,
2014; Schanen, 2006). Studies have also demonstrated associations between DNA methy-
lation and environmental factors (Herbstman et al., 2012; Perera et al., 2009; Faulk et al.,
2015; Nahar et al., 2015; Janssen et al., 2013; Saenen et al., 2016; Sen et al., 2015; Nye et al.,
2016; Bakulski et al., 2015; Cardenas et al., 2017) such as prenatal exposure to polycyclic
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aromatic hydrocarbons (PAH) (Herbstman et al., 2012; Perera et al., 2009), Bisphenol A
(Faulk et al., 2015; Nahar et al., 2015). In addition, there is evidence supporting the idea
that DNA methylation may modify the risk of environmental factors on health outcomes.
For example, Fu et al. found that DNA methylation modifies the effect of NO2 on the
progression from mild to severe asthma (Fu et al., 2012); White et al. found that DNA
methylation modifies the risk of PAH-DNA adducts on breast cancer (White et al., 2015).
Despite these findings, due to high dimensionality and low study power, current studies usu-
ally focus on finding differential methylation (DM) on health outcomes at CpG level or gene
level combining multiple CpGs and/or finding environmental effects on health outcomes but
ignoring their interactions.
Here, we developed a weighted epigenetic distance-based method with a pseudo-data
matrix constructed with cross-product terms between DNA methylation and environmental
factors that are able to capture their interactions on health outcomes. The distances between
pairs of subjects can then be calculated combining the original data matrix with DNA
methylation measures and environmental factors together with the pseudo-data matrix with
interactions. Using this approach, we can identify both main and interaction effects. We
focused on interactions between DNA methylation of CpGs in a gene and an environmental
factor on health outcomes, but the proposed method can be readily adapted to interactions
among CpGs in a gene on health outcomes. We conducted simulation studies and showed
that, when there are both main and interaction effects between DNA methylation and
environmental factors, the proposed novel approach that incorporates interactions through
a pseudo-data matrix has much better power than comparison methods that consider either
main effects or interaction effects. Most importantly, the power of the proposed method
is not affected by the source of the signals, i.e., if the signals are main or interaction
effects. This makes this approach very attractive due to the known low power of interaction
detection.
We applied the proposed method to the data from the Mothers and Newborns (MN)
birth cohort of the Columbia Center for Children’s Environmental Health (CCCEH) to
identify effects of gene-level DNA methylation, prenatal PAH and their interactions on At-
tention Deficit Hyperactivity Disorder (ADHD) at age 3. We identified some main effects of
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DNA methylation and some interactions with prenatal PAH which were missed by compar-
ison methods. Some of these findings were further replicated in the CCCEH Sibling cohort.
We similarly applied the proposed method to the Mental Development Index (MDI) at age
3 and observed a similar pattern in results in both discovery and replication analyses.
4.2 Methods
4.2.1 The proposed method
The proposed weighted distance-based method incorporating DNA methylation by environ-
ment interactions has three steps: 1) introducing a pseudo-data matrix constructed with
cross-product terms between DNA methylation of CpGs in a gene and environmental factors
that captures their interactions, on which a gene-level weighted distance matrix incorpo-
rating interactions is defined; 2) calculating the pseudo-F statistic; and 3) assessing the
statistical significance empirically using permutations. We focus on binary outcomes and
illustrate the method at the gene-level while it can be readily adapted to other types of
outcomes and to genetic region or pathway-level.
Step 1: A pseudo-data matrix and a weighted distance matrix incorporating
interactions
Here we focus on binary outcomes with equal number of cases and controls and consider
one gene with n CpGs. Denote Xm as a 2N × n matrix with DNA methylation measures
for N cases (Y = 1) and N controls (Y = 0) of n CpGs. Denote E as a 2N × 1 vector
with measures of an environment factor. Define Xmain = [Xm,E], a 2N × (n + 1) matrix
for main signals of n CpGs and one environmental factor. We normalize each column of
Xmain to have mean zero and unit standard deviation (SD). The element xmainij harbors
the normalized methylation measure of CpG j for subject i, j = 1, ..., n, and normalized
environmental factor Ei of subject i, j = n + 1, i = 1, ..., 2N . We then define X
int, a
2N ×n pseudo-data matrix with element xintij = xmainij ×Ei harbors the interaction between
CpG j and the environmental factor of subject i, j = 1, ..., n, and i = 1, ..., 2N . By using
Xmain-int = [Xmain,Xint], a 2N × (2n + 1) pseudo-data matrix, we capture main signals of
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n CpGs, one environmental factor and n pairwise CpG×E interactions.
With Xmain-int, we first define a non-weighted 2N × 2N distance matrix Dmain-int with
element dmain-intst capturing Euclidean distance between individuals s and t, s, t = 1, ..., 2N
















where ∆2E = (Es − Et)2, ∆2main, j = (Xmainsj −Xmaintj )2, and ∆2int, j = (X intsj −X inttj )2.
We then incorporate association strength at CpG site-level as weights to up-weight
signals (both main and interaction signals) and down-weight noises in calculating distances.
We define weights for main and interaction signals at CpG j and the main signal of the























where pmainj and p
int
j are P -values testing β1j = 0 and β3j = 0 in the logistic model
logitP (Yi = 1) = β0j + β1jxij + β2jEi + β3jxij × Ei, and pmainE is the P -value testing
β1E = 0 in the logistic model logitP (Yi = 1) = β0E + β1EEi.
The corresponding weighted distance matrix Dw-main-int with element dw-main-intst is de-
fined as
dw-main-intst =









Step 2: The pseudo-F statistic
To test the association between case/control status and DNA methylation distances within
a gene and an environmental factor together with their interactions, we calculate a pseudo-F
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Y is a 2N × 1 vector with case/control status, , 1 is a 2N -dimensional column vector with
elements 1, and I is a 2N × 2N identity matrix.
Step 3: The statistical significance
Permutation procedures are used to assess statistical significance, where we randomly shuf-
fle the outcome and repeat Steps 1-2 on the permuted data. When we test G genes (G > 1)
in a study, we pool G pseudo-F statistics from observed and permuted data to compute em-
pirical P -values in order to have more granular P -values (Friedman et al., 2001). We repeat







g′,perm ≥ Fw-main-intg )}
G× (1 + 999)
(4.5)
To investigate if genes with different sizes, i.e., number of CpGs, will have different
distributions for pseudo-F statistics under the null hypothesis, we conducted simulation
studies to compare the type I error rates when the P -value for each gene is calculated based
on pooled pseudo-F statistics of all G genes across all permutations (Supplementary Section
C.1.1).
4.2.2 Comparison methods
We compare the performance of the proposed method Dw-main-int that considers both main
and interaction signals with weights to that of several comparison methods, including 1)
the weighted distance-based methods considering main signals only Dw-main, 2) interaction
signals only Dw-int, 3) the distance-based methods without weights considering both main
and interaction signals Dmain-int, 4) main signals only Dmain, 5) interaction signals only
Dint, and 6) the site-level EWAS methods via logistic regressions on each CpG considering
main signals only LS or 7) both main and interaction signals LM . For LS , a simple logistic
model is fitted for each CpG in the gene one by one and a separate simple logistic model
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for the environmental factor. A significant main effect of the gene is claimed if any simple
logistic model is significant after Bonferroni adjustment for testing the number of CpGs in
the gene plus one environmental factor. For LM , a multiple logistic model with one CpG,
the environmental factor and their interaction is fitted for each CpG in a gene, and the
gene is considered significant if any multiple logistic model is significant after Bonferroni
adjustment for the number of CpGs in the gene.
4.3 Simulation studies
We conducted simulation studies to evaluate type I error rate and power of the proposed
method Dw-main-int and the comparison methods where we only considered one gene with
multiple CpGs for illustration purpose. Type I error rate is defined as the proportion of
simulations the gene is significant when the data are generated under the null hypothesis
of no association. Power is defined as the proportion of simulations the gene is significant
when the data are generated with a gene with multiple CpGs of different types of signals.
We conducted 1,000 simulations in each simulation setting.
4.3.1 Simulation setup
We simulated methylation M -values X, which are logit2 transformation of β-values (Du
et al., 2010), for samples at multiple CpGs in a gene using multivariate normal distributions.
We only considered one gene but with different number of correlated CpGs. The methylation
M -values of n CpGs of subject i are generated by
Xi ∼ Nn(µ,∆TΣ∆)
where µ = (µ1, ..., µn)
T determines means and ∆ = diag(σ1, ..., σn) determines SDs, and Σ
determines correlations among n CpGs in a gene, where we assume an AR(1) correlation
with ρ = 0.5, i.e., Σuv = ρ
|u−v|. The environmental factor of subject i is generated from
Ei ∼ Bernoulli(p) with p the probability of being exposed. We set p = 0.5. After normal-
izing each column of X and E, we calculated pairwise interactions between CpGs and the
environmental factor for subject i as Zi = Xi × Ei.
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Finally, based on the generated Xi, Ei, and Zi, Yi is generated from the following
Bernoulli distribution









where βTX, βE and β
T
Z are the effects of n CpGs, one environmental factor and n pairwise
CpG×E interactions on outcome Y .
In each simulation, we set µj ∼ N(−0.47, 3.56), j = 1, ..., n, for n CpGs, where -0.47 and
3.56 are the mean and SD of DNA methylation means of all CpGs with gene information
from the 432 samples in the CCCEH MN cohort. We set σj ∼ N(0.62, 0.21), j = 1, ..., n,
where 0.62 and 0.21 are the mean and SD of methylation SDs. We generated 100 cases and
100 controls. We set all β’s to be 0 to evaluate type I error rates and considered multiple
scenarios when signal CpGs have main signals only, interaction signals only, and both main
and interaction signals to evaluate power with null CpGs having β = 0.
4.3.1.1 Simulation settings with different types of signals
We set a gene with 30 CpGs with 1∼4 CpGs having 1) main signals only, 2) interaction
signals only, and 3) both main and interaction signals. Detailed simulation setups are in
Table 4.1.
4.3.1.2 Simulation settings with fixed number of signal items from different
number of signal CpGs
A signal item represents a signal in the data matrix Xmain-int regardless it is a main/interaction
signal. Because we consider interaction signals as another type of signal compared to main
signals, we investigated power when the same signal composition is from different number
of signal CpGs. Detailed simulation setups are in Supplementary Table C.2.
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Table 4.1: Simulation settings with different types of signals
Scenario Number of signal itemsa Simulation setupb
Main
signals only
1 signal CpG βX1 = 0.4
2 signal CpGs βX1 = βX3 = 0.4
3 signal CpGs βX1 = βX3 = βX5 = 0.4
4 signal CpGs βX1 = βX3 = βX5 = βX7 = 0.4
Interaction
signals only
1 signal CpG βZ1 = 0.4
2 signal CpGs βZ1 = βZ3 = 0.4
3 signal CpGs βZ1 = βZ3 = βZ5 = 0.4






1 signal CpG with main signals
3 signal CpGs with interaction signals βX1 = βZ3 = βZ5 = βZ7 = 0.4
(main-to-interaction signal ratio = 1:3)
2 signal CpGs with main signals
2 signal CpGs with interaction signals βX1 = βX3 = βZ5 = βZ7 = 0.4
(main-to-interaction signal ratio = 2:2)
3 signal CpGs with main signals
1 signal CpG with interaction signals βX1 = βX3 = βX5 = βZ7 = 0.4
(main-to-interaction signal ratio = 3:1)
aA signal item represents a signal in the data matrix Xmain-int no matter it is a main signal or an interaction
signal.
bX represents DNA methylation main effects, Z represents DNA methylation by environment interaction
effects.
4.3.2 Simulation results
4.3.2.1 Type I error rate
Type I error rates are well controlled at the 0.05 significance level in all simulation settings
for all methods (Table 4.2).
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Table 4.2: Type I error rates
Methods 20 CpGs* 30 CpGs 40 CpGs
Dw-main-int 0.042 0.049 0.053
Dw-main 0.050 0.052 0.057
Dw-int 0.044 0.045 0.047
Dmain-int 0.047 0.051 0.045
Dmain 0.039 0.055 0.049
Dint 0.046 0.046 0.049
LS 0.036 0.038 0.027
LM 0.037 0.039 0.035
*Number of CpGs in a gene.
4.3.2.2 Simulation settings with different types of signals
As summarized in Figure 4.1, when there are only main signals, Dw-int and Dint that only
consider interaction signals have no power, as expected. Dw-main-int is slightly less powerful
than Dw-main and similar to LS . This is because the overall main signals are diluted by the
inclusion of pseudo-data for interactions when there are no interaction signals. Dmain-int
performs similarly as LM , while both of them perform inferior to Dw-main-int with weights.
In general, the weighted versions Dw-main-int and Dw-main outperform the corresponding non-
weighted versions, suggesting that incorporating association strength weights in calculating
distances indeed helps up-weight signals and down-weight noises thus improves the overall
power.
When there are only interaction signals, Dw-main, Dmain and LS that only consider
main signals have no power, as expected. Dw-main-int is slightly less powerful than Dw-int
when both of them outperform the corresponding non-weighted versions. Dmain-int performs
similarly as LM .
When there are both main and interaction signals, we fixed the number of signal items
and the number of signal CpGs to be 4 but varying the main-to-interaction signal ratio, i.e.,
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Figure 4.1: Power results for simulation settings with main signals only, interaction signals only
and both main and interaction signals when there are 30 CpGs in a gene.
the ratio between the number of main signal CpGs and the number of interaction signal
CpGs. As the main-to-interaction signal ratio increases, the power of Dw-main, Dmain and
LS that only consider main signals increases, while that of Dw-int and Dint that only consider
interaction signals decreases, and that of Dw-main-int, Dmain-int and LM that consider both
main and interaction signals remains the same. Importantly, Dw-main-int consistently has
the largest power, which implies that the performance of Dw-main-int is not affected by signal
types. Again, the weighted versions outperform the non-weighted versions.
We also considered when there are 20 or 40 CpGs in a gene and summarized results
in Supplementary Figure C.1. We found that when we fix the number of signal CpGs but
increase the number of noise CpGs in a gene, power of non-weighted methods decreases,
while power of weighted versions is well maintained. This suggests that adding weights is
effective, especially when a smaller percent of CpGs in a gene are signals. This is consistent
with that was observed in our previous work (Wang et al., 2018).
4.3.2.3 Simulation settings with fixed number of signal items from different
number of signal CpGs
Power results for simulation settings with fixed number of signal items from different number
of signal CpGs are summarized in Supplementary Materials (Section C.1.3) and Supplemen-
tary Figure C.2. Overall, the power of distance-based methods increases as the number of
signals CpGs increases.
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4.4 Real data applications
4.4.1 CCCEH birth cohorts
Between 1998 and 2006, 727 pregnant women residing in Washington Heights, Harlem and
the South Bronx were recruited in prenatal clinics to participate in the CCCEH Mothers and
Newborns (MN) prospective cohort study. During the 3rd trimester of pregnancy, women
were asked to wear a small backpack containing a personal monitor during the daytime
for 48 hours. The collected samples were then analyzed for 8 carcinogenic PAHs (Perera
et al., 2003). The PAH metric used in the analysis is the sum of 8 carcinogenic PAHs
and was dichotomized at the median in the parent population (2.26 ng/m3). In-person
postnatal questionnaires were given when the child was 6 months and annually thereafter
with developmental questionnaires and assessments were administered every 1-2 years. We
have also measured DNA methylation in the white blood cells of umbilical cord blood.
Beginning in March 2008, pregnant women enrolled in the CCCEH MN Study were
invited to participate in the CCCEH Sibling Study. Similar to the parent study, women
were enrolled if they had a prenatal visit by the 20th week of pregnancy, and were not
active smokers or illicit drug users. The same protocol was followed as in the MN cohort.
Children were followed until age 7, with assessments of early childhood developmental and
behavioral outcomes and cord blood DNA methylation.
4.4.2 Neurodevelopment outcomes
We investigated the associations between prenatal PAH and DNA methylation on neurode-
velopmental outcomes when their interactions are considered. We assessed two neurode-
velopment outcomes at age of 3: i) Child Behavior Checklist (CBCL) DSM-IV-oriented
Attention Deficit Hyperactivity Disorder (ADHD) (Association, 2013) and ii) the Bayley
Scales of Infant Development Mental Development Index (MDI) (Bayley, 1993).
Since ADHD diagnosis at age 3 may not be clinically reliable and the main purpose is to
demonstrate the superior performance of the proposed method over comparison methods,
we dichotomized ADHD at T-score of 50 (high ADHD group T-score>50 and low with
T-score≤50), which is the median of the normed population derived from the raw scores
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(Achenbach and Rescorla, 2000). Note that a T-score of 50 was assigned to those with raw
scores below the population median, i.e., no differentiation for those below the population
median, while a percentile-type T-score was assigned to those above the population median.
We performed the discovery analysis using the MN cohort and the replication analysis using
the Sibling cohort.
For the MDI outcome, children are dichotomized as normal (MDI≥85) or moderately to
severely delayed (MDI<85) (Perera et al., 2006). Since there is only one case of moderately
to severely delayed child in the Sibling cohort, to conduct discovery and replication analyses,
we randomly split the MN cohort using 2/3 samples for the discovery analysis and 1/3 for
the replication analysis.
4.4.3 DNA methylation data processing
We conducted standard data processing steps for DNA methylation with details in Supple-
mentary Materials (Section C.2.1).
4.4.4 Risk of PAH, DNA methylation and their interactions on ADHD
There are 328 samples with complete data of DNA methylation, prenatal PAH and ADHD
in the discovery MN cohort, and 43 samples with complete data in the replication Sibling
cohort.
4.4.4.1 Discovery analysis in the MN cohort
Since the main purpose is to demonstrate the power of the proposed method Dw-main-int
over comparison methods, instead of using the Bonferroni adjustment for 18,633 genes, we
used a subjective threshold of 0.005 on the empirical gene-level P -values obtained from
the permutation procedure. At the 0.005 threshold, Dw-main-int identified 10 genes in the
discovery analysis, with 7 due to main signals only and 3 due to interaction signals only
(Table 4.3).
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Table 4.3: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 10 genes by the proposed method Dw-main-int at the 0.005
gene-level P -value threshold
Rank in Dw-main-int Gene # CpG Rank in Dw-main Rank in Dw-int
1 LOC84931 * 9 1 1513
2 SERPINB3 1 2 18316
3 CYP2E1 * 13 6041 1
4 MIR518E 1 15105 2
5 KIR3DP1 1 18630 3
6 KRTAP20-1 1 10 18472
7 IGJ 1 4 18286
8 ADAM32 11 5 15841
9 HIST1H2BJ * 4 3 14178
10 CXCL9 1 11 16665
*Genes replicated in the replication analysis.
4.4.4.2 Replication analysis in the Sibling cohort
Due to the small sample size of the Sibling cohort, we used a gene-level P -value threshold of
0.1 in the replication analysis. Among the 10 genes identified in the discovery MN cohort, 3
(LOC84931, CYP2E1 and HIST1H2BJ ) were replicated in the replication Sibling cohort.
In both discovery and replication analyses, gene CYP2E1 was identified due to interaction
signals, and genes LOC84931 and HIST1H2BJ were identified due to main signals.
Figure 4.2 plots boxplots of methylation measures of the 13 CpGs in gene CYP2E1, iden-
tified and replicated due to interaction signals, stratifying by PAH and ADHD. Eight out of
the 13 CpGs have clear interaction signals in the discovery data, when all 8 showed interac-
tion signals in the same direction in the replication data. It was reported that prenatal expo-
sure to serotonin reuptake inhibitor antidepressants modifies the association between DNA
methylation at regulatory region of CYP2E1 and 3rd trimester maternal depressed mood
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Figure 4.2: Boxplot of DNA methylation measures of the 13 CpGs in gene CYP2E1 stratified by
PAH and ADHD status in the (A) discovery analysis using the MN cohort, and the (B) replication
analysis using the Sibling cohort. Here p(m) and p(i) are Bonferroni-adjusted (for number of CpGs
in gene CYP2E1 ) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model: logitP (Y =
1) = β0 + β1CpG + β2E + β3CpG× E.
symptoms (Gurnot et al., 2015). Elevated DNA methylation in the promoter-regulatory
region of the gene CYP2E1 was also reported to be associated with severe psychosocial
deprivation in early childhood and socio-cognitive impairment (Kumsta et al., 2016). We
similarly plotted for genes LOC84931 and HIST1H2BJ (Supplementary Figures C.3, C.4).
4.4.4.3 Results of the comparison methods
At the same 0.005 P -value threshold, the comparison methods identified different number
of genes (Supplementary Tables C.3-C.9), when all these genes rank within top 3% of the
proposed method results. The comparison methods have replication rates 0-40% with an
average 14% (Supplementary Table C.10). Detailed results are in Supplementary Materials
(Section C.2.2.2).
4.4.5 Risk of PAH, DNA methylation and their interactions on MDI
Two-third MN samples (n=216) were used for the discovery analysis and 1/3 (n=94) for
the replication analysis.
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Table 4.4: Application examining prenatal PAH, DNA methylation and their interactions
on child MDI at age 3 identified 7 genes by the proposed method at the 0.005 gene-level
P -value threshold
Rank in Dw-main-int Gene # CpG Rank in Dw-main Rank in Dw-int
1 UROS 2 2 18516
2 FAM35A* 7 1 15325
3 DIRC1 * 3 6 17815
4 MIR521-1 1 16 18302
5 C8orf80 * 4 3 2329
6 THSD1P* 5 7 15099
7 C19orf77 9 5 647
*Genes replicated in the replication analysis.
4.4.5.1 Discovery analysis in the discovery data
At the same 0.005 P -value threshold, the proposed method Dw-main-int identified 7 genes
in the discovery analysis, with 5 due to main signals only and 2 due to both main and
interaction signals (Table 4.4).
4.4.5.2 Replication analysis in the replication data
At the same 0.1 gene-level P -value threshold for replication, 3 genes, FAM35A, DIRC1 and
THSD1P, were replicated in the replication analysis due to main signals out of the 5 genes
identified in the discovery analysis due to main signals only. Gene C8orf80 was replicated
due to interaction signals, out of the 2 genes identified in the discovery analysis due to
both main and interaction signals. That is, the replication rate is 57% with 4 out of 7
genes replicated. Figure 4.3 plots boxplots of DNA methylation measures of the 4 CpGs
in gene C8orf80 stratified by PAH and MDI status that was identified due to both main
and interaction signals and replicated due to interaction signals. We similarly plotted genes
FAM35A, DIRC1 and THSD1P (Supplementary Figures C.5-C.7).
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Figure 4.3: Boxplots of DNA methylation measures of the 4 CpGs in gene C8orf80 stratified by
PAH and MDI status in the (A) discovery analysis using the 2/3 MN discovery data, and the (B)
replication analysis using the 1/3 MN replication data. Here p(m) and p(i) are Bonferroni-adjusted
(for number of CpGs in gene C8orf80 ) P -values testing β1 = 0 and β3 = 0 in the multiple logistic
model: logitP (Y = 1) = β0 + β1CpG + β2E + β3CpG× E.
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4.4.5.3 Results of the comparison methods
All genes identified by the comparison methods rank within top 2% of the proposed method
results. The comparison methods have replication rates 0-25% with an average 9% (Sup-
plementary Table C.11 and details in Supplementary Materials Section C.2.3).
4.5 Discussion
We developed a novel weighted distance-based method Dw-main-int that considered interac-
tions between CpGs in a gene and an environmental factor through constructing a pseudo-
data matrix with their cross-product terms. The proposed approach is powerful and flexible
with several advantages. First, the weighted distance matrix Dw-main-int always has a di-
mension N × N with N being the sample size regardless the added dimensionality from
pairwise interactions. Second, by calculating distances between pairs of individuals across
CpGs and their interactions with an environmental factor, weak main/interaction signals are
accumulated, boosting the study power. Third, incorporating association strength weights
in calculating distances helps up-weight signals and down-weight noises thus further im-
proves the overall power, especially when a small percent of CpGs in a gene are signals.
Most importantly, simulation results suggest that when the main-to-interaction signal ratio
decreases, i.e., when the number of main signals decreases or the number of interaction sig-
nals increases but fixing the total number of signal items, the proposed method Dw-main-int
maintains similar power and almost achieves the highest power among all comparison meth-
ods, while the comparison methods have power drop. This makes the proposed approach
especially attractive due to the known low power in detecting interactions.
In the application to the CCCEH MN and Sibling cohorts examining prenatal PAH,
DNA methylation and their interactions on child ADHD at age 3, Dw-main-int identified 10
genes in the discovery data with 3 replicated in the replication data, while the comparison
methods have an average replication rate 14%. In another application on child MDI at age
3, Dw-main-int identified 7 genes in the discovery data with 4 replicated in the replication
data, while the comparison methods have an average replication rate 9%.
In general, the proposed method that considers both main and interaction signals has
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a superior performance than methods that consider only one type of signals when there
are both. The weighted versions are always more powerful than non-weighted versions,
especially when a small percentage of CpGs in a gene have weak signals. The proposed
method was developed for DNA methylation by environment interactions but can be readily
extended to CpG by CpG interactions similarly using a pseudo-data matrix constructed with
cross-product terms between CpGs. However, the dimension of this pseudo-data matrix
capturing pairwise CpG by CpG interactions goes up exponentially, which could easily out-
number the dimension of CpGs in the gene. We need to take extra caution to balance
between main or interaction signals, especially when assigning weights.
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Chapter 5
Conclusions
In this dissertation, new statistical methods for DNA methylation data were developed
focusing on detection of differential variation and interactions in order to fill in the gaps
in these areas. These work were especially motivated by recent obervations that DV con-
tributes to early epigenetic alterations in carcinogenesis, namely epigenetic field defects.
Identifying epigenetic field defects is important for early cancer detection, however, exist-
ing statistical methods are not powerful enough to detect these early epigenetic alterations
comparing normal tissues and normal-adjacent tissues to tumor tissues when the differences
are usually minimum.
We developed two methods to detect epigenetic field defects with weak CpG site-level
signals. The first method utilizes the dependency among neighboring CpGs to identify
differentially methylated regions through combining both DM and DV signals, where in
combining the two types of signals, we weighted them differently to balance the contri-
bution of DM and DV signals to the combined score. The suprior performance of the
proposed method was demonstrated through simulation studies and applications to 450K
DNA methylation data of tumor and normal-adjacent tissues of breast invasive carcinoma
(BRCA) and kidney renal clear cell carcinoma (KIRC) from The Cancer Genome Atlas
(TCGA) project. We identified some cancer-related genes that were missed by the DMR
detection methods that use only DM signals or DV signals. The application to an indepen-
dent 450K DNA methylation data of BRCA tumor and normal-adjacent tissues from Gene
Expression Omnibus (GEO) allowed us to replicate some of the detected DMRs and we
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concluded that DMRs detected using variance signals are reproducible. Further application
to the DNA methylation data of GEO BRCA normal-adjacent tissues from breast cancer
patients and normal tissues from age-matched cancer-free women identified epigenetic field
defects in two DMRs. Further comparisons between tumor tissues from breast cancer pa-
tients to normal tissues from age-matched cancer-free women confirmed that the epigenetic
field defects are enriched in the progression to breast cancer. Most importantly, the epige-
netic field defects were only identified by the developed new DMR detection method that
uses DM and DV combined signals.
The second method accumulates weak DM and DV signals at CpG site-level across CpGs
in a gene to detect genes with epigenetic field defects. This is achieved through construct-
ing a pseudo-data matrix with centered quadratic terms of DNA methylation measures that
captures DV signals. The epigenetic distances between pairs of subjects can then be cal-
culated combining the original data matrix with measures of DNA methylations together
with the pseudo-data matrix with quadratic terms of DNA methylation. Using this ap-
proach, we accumulate weak DM and DV signals at CpG site-level across CpGs in a gene.
CpG site-level association strengths were added as weights to up-weight signal CpGs and
down-weight noise CpGs to further boost the study power. We demonstrated the suprior
performance of the proposed method through simulation studies and an application to the
the same 450K DNA methylation data of normal-adjacent tissues of BRCA patients and
normal tissue from independent age-matched cancer-free women from GEO. The proposed
method identified genes with epigenetic field defects that were missed by standard EWAS
methods and non-weighted distance-based methods, with many of these epigenetic field de-
fects being previously reported to be associated with breast cancer. We further confirmed
their enrichment in the progression to breast cancer and replicated some of these identified
epigenetic field defects in an independent data.
Other than the known crucial role of DNA methylation in humna health, studies have
also demonstrated associations between DNA methylation and environmental factors with
evidence also supporting the idea that DNA methylation may modify the risk of environmen-
tal factors on health outcomes. However, due to high dimensionality and low study power,
current studies usually focus on finding DM on health outcomes at CpG level or gene level
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combining multiple CpGs and/or finding environmental effects on health outcomes but ig-
noring their interactions on health outcomes. We developed a powerful and flexible weighted
distance-based method that incorporates interactions between DNA methylation and envi-
ronmental factors on health outcomes. This is achieved through constructing a pseudo-data
matrix with cross-product terms between DNA methylation and environmental factors that
capture interactions between them. The distances between pairs of subjects can be sim-
ilarly calculated combining the original data matrix with measures of DNA methylation
and environmental factors together with the pseudo-data matrix with interactions. Using
this approach, we can identify both main and interaction effects. CpG site-level association
strengths were added as weights to up-weight signal CpGs and down-weight noise CpGs
to further boost the study power. The proposed approach is powerful and flexible with
several advantages. First, the weighted distance matrix always has a dimension of N ×N
with N being the sample size regardless the added dimensionality from pairwise interac-
tions. Second, by calculating distances between pairs of individuals across CpGs and their
interactions with an environmental factor, weak main/interaction signals are accumulated,
boosting the study power. Most importantly, simulation results suggest that when the
main-to-interaction signal ratio decreases, i.e., when the number of main signals decreases
or the number of interaction signals increases but fixing the total number of signal items, the
proposed method maintains similar power and almost achieves the highest power among all
comparison methods, while the comparison methods have power drop. That is, the power
of the proposed method is not affected by the source of the signals, i.e., if the signals are
main or interaction effects. This makes the proposed approach especially attractive due
to the known low power in detecting interactions. In the application to the data from the
Mothers and Newborns (MN) birth cohort of the Columbia Center for Children’s Environ-
mental Health (CCCEH) to identify effects of gene-level DNA methylation, prenatal PAH
and their interactions on Attention Deficit Hyperactivity Disorder (ADHD) at age 3, we
identified some main effects of DNA methylation and some interactions with prenatal PAH
which were missed by comparison methods. Some of these findings were further replicated
in the CCCEH Sibling cohort. We similarly applied the proposed method to the Mental De-
velopment Index (MDI) at age 3 and observed a similar pattern in results in both discovery
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and replication analyses.
Since the weighted distance matrix always has a dimension of N ×N with N being the
sample size regardless the added dimensionality from pairwise interaction terms, it can also
be extended to CpG by CpG interactions similarly using a pseudo-data matrix constructed
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A.1 Investigation of the distance limits to define clusters
We investigated the relationship between the choice of distance limit, the maximal distance
between two neighboring sites to be included in a cluster, and the distribution of the dif-
ference in the combined signals scores (before smoothing) between neighboring CpG sites
using TCGA BRCA data of tumor and normal-adjacent tissues.
Within each chromosome, we ordered the combined signal scores by their genomic lo-
cations and calculated the differences in the combined signals scores between neighboring
CpG sites. We then change the distance limits from 300 bp to 2,000 bp (300 bps, 500
bps, 700 bps, 1,000 bps, 1,500 bps, and 2,000 bps) and plotted the distribution of the dif-
ferences for neighboring CpG sites whose distance is less than the specified distance limit
(Figure A.1). We found that the mean and SD in the difference in combined signal scores
between neighboring CpG sites increases as the distance limits increases. In the developed
algorithm, users could choose other distance limits as an option.
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Distance Limitation = 300 bp 
 (mean = 0, SD = 2.91)




















Histogram of difference in combined signal scores between neighboring CpGs using different distance limitation to define clusters
Distance Limitation = 500 bp 
 (mean = 0, SD = 3.14)




















Distance Limitation = 700 bp 
 (mean = 0.01, SD = 3.3)




















Distance Limitation = 1000 bp 
 (mean = 0.01, SD = 3.48)




















Distance Limitation = 1500 bp 
 (mean = 0.01, SD = 3.67)




















Distance Limitation = 2000 bp 
 (mean = 0.02, SD = 3.81)




















Figure A.1: Histogram of the difference in the combined signal scores for neighboring CpG sites with the
choice of difference distance limits.
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A.2 Simulation studies for case-control designs
We adapted the proposed new DMR detection method for case-control designs and con-
ducted simulation studies parallel as for matched case-control designs in the main text
to evaluate the type I errors and the performance. We compared the performance of the
new method with those DMR detection methods that consider 1) mean signals only using
two-sided two-sample t-test, the bump hunting method (Jaffe et al., 2012c), the modified
bump hunting method which divide the regression coefficient estimates from the original
bump hunting method by their standard errors; and 2) variance signals only using one-sided
F -test, where we applied the same smoothing step and the same significance assessment
step.
A.2.1 Simulation setup
To simulate DNA methylation measures of tumor and normal tissues, we assume logit2




where lk is the size of the k-th cluster, and the mean vector µ = (µ1, ..., µlk)
T and diagonal




δlk) controls the mean and variance signals. Σ is a variance-
covariance matrix (lk × lk) considering correlations among lk CpG sites within the k-th
pre-defined cluster. Here we assume an AR(1) correlation with correlation coefficient ρ,
i.e., Σmn = σ × ρ|m−n| . We set ρ = 0.5 in the simulation studies similarly as in matched
case-control designs, and set σ = 0.25. In each simulation, we generated methylation M -
values of 10,000 sites from 100 cancer patients and 100 normal controls, where the genomic
locations of these 10,000 sites are the first 10,000 sites of Chromosome 1 on the Illumina
450K array.
Since DNA methylation measures are known to be associated with variables such as
age (Christensen et al., 2009; Teschendorff et al., 2010) and gender (Liu et al., 2010), we
work on methylation residuals after adjusting for such confounders. We investigated type
I errors to examine if using methylation residuals controls potential spurious DMRs due to
unbalanced distribution of confounders, such as gender. More specifically, we set 50% of
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cancer patients to be female while only 20% of normal controls to be female. We simulated
10 spurious DMRs each having 10 CpG sites, within which we set µ = 1 for both tumor and
normal tissues in the female group, while µ = 0 for both tumor and normal tissues in the
male group. For all other sites, we set µ = 0 for tumor and normal tissues in both gender
groups. We considered two scenarios where we applied the new method on: 1) methylation
residuals obtained from regressing methylation M -values on gender using linear models,
and 2) methylation M -values directly ignoring gender. We conducted 1,000 simulations in
each scenario.
In sections to evaluate the performance of the new method, we assume confounders are
already accounted for when methylation residuals are used. We simulated 10 true DMRs
with different region sizes varying from 3 to 15 CpG sites, and we considered scenarios when
each CpG site in the true DMRs has 1) mean signals only, 2) variance signals only, and 3)
both mean and variance signals. For all other null sites, we set µ = 0 and σ = 0.25. For
each simulation scenario, we conducted 1,000 simulations.
A.2.2 Simulation results
The type I errors of the new method that considers both mean and variance signals, the
two-sample t-test that considers mean signals only, and the F -test that considers variance
signals only were all well controlled at 0.039, 0.023 and 0.059 when applied to methylation
residuals. When applied to the methylation measures ignoring the gender effect, the type I
errors were all inflated at 1.000, 1.000 and 0.997. The type I errors of bump hunting (Jaffe
et al., 2012c) and modified bump hunting that directly adjust for gender effect were both
well controlled at 0.041. The region size was set at L ≥ 3 CpG sites.
The ROC curves from the setting with 10 true DMRs having different region sizes are
shown in Figure A.2. Similar patterns as in matched case-control designs are observed.
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(A) Mean Signals Only


























(B) Variance Signals Only






















(C) Both Mean and Variance Signals















Figure A.2: ROC curves from simulation studies when 10 true DMRs have different region sizes varying
from 3 to 15 CpG sites with: (A) mean signals only; (B) variance signals only; and (C) both mean and
variance signals. DMRs were defined as regions with minimum region size L ≥ 3 CpG sites.
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A.3 Real data application
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Table A.2: 7 Cancer-Related Genes Identified in the Top 10 Ranked DMRs in TCGA KIRC Dataa
Cancer Gene
Breast Cancer MCF2L2 (Legendre et al., 2015)
Colorectal Cancer GAD2 (Li et al., 2012)
Endometrial Carcinoma PAX2 (Wu et al., 2005)
Hepatocellular Carcinoma DCAF4L2 (Song et al., 2013)
Melanoma GPR98 (Harvey et al., 2013)
Pancreatic Cancer FOXL1 (Zhang et al., 2013a)
Stomach Cancer RIMS2 (Ewing et al., 2015)
a: There are 10 genes in the top 10 ranked DMRs out of 100 significant DMRs that were uniquely identified by the
new method (compared with all five competing methods except for DMRcate), and 7 genes were previously reported
to be cancer-related.
Table A.3: 11 Cancer-Related Genes Identified in the Top 10 Ranked DMRs in GEO BRCA Data
(Tumor vs. Normal-adjacent) a
Cancer Gene
Breast Cancer CBX8 (Lee et al., 2013), NXPH1 (Faryna et al., 2012)
Colorectal Cancer VIM (Costa et al., 2010), WNT1 (He et al., 2005)
Gastric Cancer FOXD3 (Cheng et al., 2013), RASGRF1 (Takamaru et al., 2012)
Lung Cancer C6orf176 (Chen et al., 2016)
Ovarian Cancer HIST1H3G (Zhang and Luo, 2016), HIST1H2BI (Hong et al., 2010), VCAN (Ghosh et al., 2010)
Prostate Cancer GFRA1 (Huber et al., 2015)
a: There are 12 genes in the top 10 ranked DMRs out of 37 significant DMRs that were uniquely identified by the
new method (compared with all five competing methods except for DMRcate), and 11 genes were previously reported
to be cancer-related.
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Figure A.3: DMR #1 (top row) and #2 (bottom row) located on chromosomes 10 and 8 (out of 170
DMRs) that were identified uniquely by the new method in the TCGA KIRC data. The vertical dash lines
define the boundaries of the DMRs. Left column shows the combined signal scores of sites in the identified
DMRs before (circles) and after (curve) smoothing, where the horizontal dotted line defines the threshold
k to define a candidate region. Right column shows the mean differences and SD ratios in methylation
measures of sites in the identified DMRs between tumor and normal-adjacent tissues.
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Figure A.4: DMR #1 (top row) and #2 (bottom row) located on chromosomes 1 and 10 (out of 89 DMRs)
that were identified uniquely by the new method in the GEO BRCA tumor vs. normal-adjacent data. The
vertical dash lines define the boundaries of the DMRs. Left column shows the combined signal scores of
sites in the identified DMRs before (circles) and after (curve) smoothing, where the horizontal dotted line
defines the threshold k to define a candidate region. Right column shows the mean differences and SD ratios
in methylation measures of sites in the identified DMRs between tumor and normal-adjacent tissues. There
are 3 gene, SGCE, PEG10 and PHOX2B in these 2 DMRs. SGCE was reported to be associated with
colorectal cancer (Ortega et al., 2010), PEG10 was reported to be associated with hepatocellular carcinoma
(Ip et al., 2007), and PHOX2B was reported to be associated with neuroblastoma (De Pontual et al., 2007)
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Figure A.5: Distributions of genome-wide site-level scale parameter λi in the GEO BRCA data. From left
to right shows distribution of λi in (1) normal-adjacent vs. normal, (2) tumor vs. normal-adjacent, and (3)
tumor vs. normal comparisons.
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Figure A.6: DMR #1 (top row) and #2 (bottom row) located on chromosomes 10 and 12 that were
identified uniquely by the new method in the GEO BRCA normal-adjacent vs. normal data. The vertical
dash lines define the boundaries of the DMRs. Left column shows the combined signal scores of sites in
the identified DMRs before (circles) and after (curve) smoothing, where the horizontal dotted line defines
the threshold k to define a candidate region. Right column shows the mean differences and SD ratios in
methylation measures of sites in the identified DMRs between normal-adjacent and normal tissues.
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Figure A.7: DMR #1 (top row) and #2 (bottom row) located on chromosomes 6 (out of 15 DMRs)
that were identified uniquely by the new method in the GEO BRCA tumor vs. normal data. The vertical
dash lines define the boundaries of the DMRs. Left column shows the combined signal scores of sites in
the identified DMRs before (circles) and after (curve) smoothing, where the horizontal dotted line defines
the threshold k to define a candidate region. Right column shows the mean differences and SD ratios in
methylation measures of sites in the identified DMRs between tumor and normal tissues.
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B.1 Additional Simulation Studies
B.1.1 Effects of gene sizes in Type I errors
To investigate if genes with different sizes, i.e., number of CpGs, will have different distri-
butions for pseudo-F statistics under the null hypothesis, we conducted simulation studies
to evaluate type I error rates of the proposed method and those of the comparison methods.
Specifically, we simulated methylation measures for 16 genes that consist of 1, 5, 10, 15,
20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, and 100 CpGs, respectively. When calculating the
P -value for each gene, we (1) pool all pseudo-F statistics of the 16 genes across all permu-
tations, and (2) only use pseudo-F statistics of that particular gene across all permutations.
Type I error rate is defined as the proportion of simulations with any significant genes when
the data is generated under the null hypothesis of no genes are associated with case-control
status.
Table B.1: Type I error rates in simulation settings with multiple genes of different sizes
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B.1.2 Values of shape parameters in simulations
We set a0 = 46.36 and b0 = 52.28 for all CpGs in controls and noise CpGs in cases such
that a beta distirbution Beta(a0, b0) has a mean 0.47 and a SD 0.05, mimicing the real
GEO methylation data. The values of a1 and b1 for signal CpGs in cases and the mean
and SD of the corresponding beta distributions are summarized in Supplementary Table B.2.












29.5 33.27 0.47 0.0625 0 1.25
20.34 22.94 0.47 0.075 0 1.50
14.82 16.71 0.47 0.0875 0 1.75
11.24 12.67 0.47 0.10 0 2
8.78 9.90 0.47 0.1125 0 2.25
7.02 7.92 0.47 0.125 0 2.50
Mean signal
only
48.49 50.47 0.49 0.05 0.02 1
50.47 48.49 0.51 0.05 0.04 1
52.28 46.36 0.53 0.05 0.06 1
53.90 44.10 0.55 0.05 0.08 1
55.31 41.73 0.57 0.05 0.10 1
1Mean difference in the signal CpG between cases and controls.
2SD ratio in the signal CpG between cases and controls.
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B.1.3 Simulation settings with one gene considering correlations among
CpGs
We conducted simulation studies to investigate the impact of correlations among neighbor-
ing CpGs on the performance of the proposed distance-based method. We simulated DNA
methylation M -values which are the logit2 transformation of methylation β-values, and con-
sidered AR(1) correlation among CpGs in a gene with a correlation coefficient ρ=0.5. Here
we only considered one gene for illustration purposes, and conducted simulation studies
parallel as that for methylation β-values in the main text. More specifically, We considered
one gene with different signal-to-noise ratios ranging from 1:0, 1:24, 1:49, 3:47, to 5:45. We
considered scenarios when signal CpGs have different mean or variance signals by varying
means and SDs of a normal distribution used to generate methylation M -values. We consid-
ered scenarios when mean differences in methylation M -values between cases and controls
are 0.25×SD0, 0.5×SD0, 0.75×SD0, 1×SD0 and 1.25×SD0 where SD0 is the SD in con-
trols. We also considered scenarios when ratios of SDs for cases and controls are 1.25, 1.50,
1.75, 2 and 2.25.
Type I error rates are well controlled at the 0.05 significance level in all scenarios (Sup-
plementart Table B.3). Power results are summarized in Supplementary Figure B.1 where
we note that the power patterns are very similar to those observed in simulations based
on methylation β-values without considering correlations among CpG sites. This implies
that the correlations among neighboring CpGs in a gene do not have much impact on the
performance of the proposed distance-based method, neither does the use of methylation
M -values or β-values.
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Table B.3: Type I error rates in simulation settings with AR(1) correlation among neigh-
boring CpGs with ρ = 0.5
Method 1 CpG 25 CpGs 50 CpGs
Dw−DM−DV 0.044 0.044 0.042
Dw−DM 0.057 0.050 0.040
Dw−DV 0.042 0.053 0.042
DDM−DV 0.044 0.043 0.042
DDM 0.057 0.048 0.043
DDV 0.043 0.057 0.048
EWASDM 0.054 0.044 0.046
EWASDV 0.052 0.039 0.032
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Figure B.1: Power results for simulation settings with one gene considering AR(1) correlation
among neighboring CpGs with correlation coefficient ρ=0.5. The signal gene has one signal CpG
and increasing number of total CpGs, i.e., decreasing signal-to-noise ratios from 1:0, 1:24 to 1:49
(panel A for mean signals only, panel B for variance signals only), or with a fixed total number of
CpGs 50 and increasing signal-to-noise ratios from 1:49, 3:47, to 5:45 (panel C for mean signals only,
panel D for variance signals only).
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B.2 Real data application
B.2.1 Discovery analysis
Table B.4: 11 genes identified by Dw−DM at the 0.0005 gene-level P -value threshold in the
GEO BRCA Data
Rank Gene # CpG Rank in Dw−DM−DV Rank in EWASmin−P
1 ZFP57 * 5 2 16
2 RGL3 21 45 66
3 ANKRD13B* 22 5 25
4 PENK * 23 6 37
5 MMP23B* 2 17 80
6 MIR564 9 86 55
7 HBA1 * 7 10 23
8 SSTR4 9 29 197
9 PPP3R1 11 30 299
10 TRH * 16 13 28
11 SOX1 28 33 86
*Genes also identifed by Dw−DM−DV .
Table B.5: 9 genes identified by Dw−DV at the 0.0005 gene-level P -value threshold in the
GEO BRCA Data
Rank Gene # CpG Rank in Dw−DM−DV Rank in EWASmin−P
1 KDM5A* 2 9 4
2 CXCL6 * 7 8 1
3 DPH3B* 5 3 61
4 TMC4 * 13 1 2
5 ANGPTL3 3 158 50
6 IL4R 12 46 31
7 NAA35 * 7 4 10
8 TMEFF1 * 5 18 156
9 THY1 * 19 7 13
*Genes also identifed by Dw−DM−DV .
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Table B.6: 2 significant genes identified by DDM−DV at the 0.0005 gene-level P -value
threshold in the GEO BRCA Data
Rank Gene # CpG Rank in Dw−DM−DV Rank in EWASmin−P
1 MMP23B* 2 17 80
2 ZNF154 12 26 202
*Genes also identifed by Dw−DM−DV .
Table B.7: 6 genes identified by DDM at the 0.0005 gene-level P -value threshold in the
GEO BRCA Data
Rank Gene # CpG Rank in Dw−DM−DV Rank in EWASmin−P
1 MMP23B* 2 17 80
2 ZNF154 12 26 202
3 TRH * 16 13 28
4 SOX17 18 59 609
5 WFDC3 2 392 106
6 SPAG6 * 16 11 170
*Genes also identifed by Dw−DM−DV .
Table B.8: 4 significant genes identified by DDV at the 0.0005 gene-level P -value threshold
in the GEO BRCA Data
Rank Gene # CpG Rank in Dw−DM−DV Rank in EWASmin−P
1 C7orf11 1 386 126
2 MIR1305 1 443 78
3 KDM5A* 2 9 4
4 ANGPTL3 3 158 50
*Genes also identifed by Dw−DM−DV .
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Figure B.2: Heatmaps of original DNA methylation measures of the 50 normal tissues, 42 normal-
adjacent tissues together with the 42 matched tumor tissues for 14 genes uniquely identified by
Dw−DM−DV .
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Figure B.3: Heatmaps of original DNA methylation measures of the 50 normal tissues, 42 normal-
adjacent tissues together with the 42 matched tumor tissues for 7 genes uniquely identified by
EWASmin−P .
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Figure B.4: Heatmaps of original DNA methylation measures of the 50 normal tissues, 42
normal-adjacent tissues together with the 42 matched tumor tissues for 7 genes identified by both
Dw−DM−DV and EWASmin−P .
APPENDIX B. APPENDIX TO DETECTION OF EPIGENETIC FIELD DEFECTS










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.5: DNA methylation measures of 50 normal tissues, 42 normal-adjacent tissues and 42
matched tumors of 16 CpGs in the CFTR gene that was uniquely identified by Dw−DM−DV , but
ranked the last using EWASmin−P among all uniquely identified genes. Pm and Pv are P -values
from CpG site-level mean and variance tests that are adjusted for multiple comparisons for the
number of CpGs in the gene. The three horizontal lines represent mean methylation levels of the
three groups of normal tissues, normal-adjacent tissues and matched tumors.
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Figure B.6: DNA methylation measures of 50 normal tissues, 42 normal-adjacent tissues and 42
matched tumors of 16 CpGs in the PLS1 gene that was uniquely identified by EWASmin−P , but
ranked the last using Dw−DM−DV among all uniquely identified genes. Pm and Pv are P -values
from CpG site-level mean and variance tests that are adjusted for multiple comparisons for the
number of CpGs in the gene. The three horizontal lines represent mean methylation levels of the
three groups of normal tissues, normal-adjacent tissues and matched tumors.
APPENDIX B. APPENDIX TO DETECTION OF EPIGENETIC FIELD DEFECTS











































































































































































































































































Figure B.7: Weighted distance matrices for genes CFTR and PLS1.
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Figure B.8: DNA methylation measures of 50 normal tissues, 42 normal-adjacent tissues and 42
matched tumors of 13 CpGs in the TMC4 gene that was identified by both Dw−DM−DV and
EWASmin−P and ranked on #1 and #2, respectively. Pm and Pv are P -values from CpG site-level
mean and variance tests that are adjusted for multiple comparisons for the number of CpGs in the
gene. The three horizontal lines represent mean methylation levels of the three groups of normal
tissues, normal-adjacent tissues and matched tumors.
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Figure B.9: The selection probability of identifying a gene out of all genes of the same size.
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21 genes identified by  Dw −DM−DV
Figure B.10: −log10(p-value) from CpG site-level t-tests in (1) normal-adjacent versus normal
comparison and (2) unmatched tumor versus normal-adjacent comparison in the GEO BRCA data
for 21 genes identified by Dw−DM−DV .
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B.2.3 Replication analysis
Table B.9: Summary number of genes identified by comparison methods in both the dis-
covery analysis and replication analysis at the 0.0005 gene-level P -value threshold
Method
# of gene replicated /
identified in discovery data
Replicated genes
Dw−DM−DV 7/21
DPH3B, NAA35, ANKRD13B, CXCL6,
FKBP4, PRSS48, CFTR
Dw−DM 4/11 ANKRD13B, MMP23B, PPP3R1, MIR564
Dw−DV 1/9 ANGPTL3
DDM−DV 2/2 MMP23B, ZNF154
DDM 2/6 MMP23B, ZNF154
DDV 1/4 C7orf11
EWASmin−P 11/14
NAA35, THY1, CXCL6, FKBP4, TMEM200B,
FAM198B, NRBP1, NOL6, STAU2, SALL1, PLS1
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7 replicated genes identified by  Dw −DM−DV
Figure B.11: −log10(P -value) from CpG site-level t-tests in (1) normal-adjacent versus normal
comparison and (2) unmatched tumor versus normal-adjacent comparison in the replication analysis
for 7 replicated genes identified by Dw−DM−DV .
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We plotted the DNA methylation measures for 18 normal samples from the replication
data (GSE67919), 50 normal samples, 42 normal-adjacent samples and 42 matched tumor
samples from the discovery data (GSE69914) (Supplementary Figure B.12) for all CpGs
in the CFTR gene. In the discovery analysis, the CFTR gene was uniquely identified
by Dw−DM−DV but ranked the last using EWASmin−P among all Dw−DM−DV uniquely
identified genes. The CFTR gene was replicated in the replication data by Dw−DM−DV
due to weak dense signals similarly as in the discovery analysis. As the second example, we
plotted the DNA methylation measures of all CpGs in the CXCL6 gene, which was identified
in the discovery analysis by both Dw−DM−DV and EWASmin−P and was replicated by both
methods in the replication data (Supplementary Figure B.13). It is clear that all CpGs in
the CXCL6 gene have weak signals, and some of these weak dense signals were mainly due
to a few outlier normal-adjacent tissue samples which was also observed in the discovery
analysis. All CpGs in the CXCL6 gene showed enrichment in methylation measures in the
progression to tumor.
Among the 14 genes identified by EWASmin−P in the discovery analysis, 11 were repli-
cated in the replication data, which are CXCL6, TMEM200B, NRBP1, SALL1, FKBP4,
NOL6, PLS1, NAA35, STAU2, THY1, and FAM198B. We similarly plotted the DNA
methylation measures of all CpGs in the PLS1 gene (Supplementary Figure B.14) of the
samples in the replication data. In the discovery analysis, the PLS1 gene was uniquely
identified by EWASmin−P but ranked the last using Dw−DM−DV among all EWASmin−P
uniquely identified genes, and we found that it was identified mainly due to the strong vari-
ance signal at the CpG site cg00137209 as a result of very small variation in the methylation
measures of the 50 normal tissues in the discovery data. In the replication analysis, however,
the PLS1 gene was replicated due to the mean signal at a different CpG site cg21213806.
This implies that the PLS1 gene might not be reliable, even it was replicated.
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Figure B.12: DNA methylation measures of 18 normal tissues from the replication data
(GSE67919), 50 normal tissues, 42 normal-adjacent tissues and 42 matched tumors from the discov-
ery data (GSE69914) of 16 CpGs in the CFTR gene that was uniquely identified in the discovery
analysis and replicated by Dw−DM−DV . Pm1 and Pv1 are P -values from CpG site-level mean and
variance tests that are adjusted for multiple comparisons for the number of CpGs in the gene from
the discovery analysis, and Pm2 and Pv2 are those from the replication analysis. Highlighted are
the minimum adjusted DM and DV P -value across all P -values in the gene in each comparison. The
four horizontal lines represent mean methylation levels of the four groups of tissues.
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Figure B.13: DNA methylation measures of 18 normal tissues from the replication data
(GSE67919), 50 normal tissues, 42 normal-adjacent tissues and 42 matched tumors from the discov-
ery data (GSE69914) of 7 CpGs in the CXCL6 gene which was identified in the discovery analysis
and replicated by both Dw−DM−DV and EWASmin−P . Pm1 and Pv1 are P -values from CpG site-
level mean and variance tests that are adjusted for multiple comparisons for the number of CpGs
in the gene from the discovery analysis, and Pm2 and Pv2 are those from the replication analysis.
Highlighted are the minimum adjusted DM and DV P -value across all P -values in the gene in each
comparison. The four horizontal lines represent mean methylation levels of the four groups of tissues.
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Figure B.14: DNA methylation measures of 18 normal tissues from the replication data
(GSE67919), 50 normal tissues, 42 normal-adjacent tissues and 42 matched tumors from the discov-
ery data (GSE69914) of 16 CpGs in the PLS1 gene that was uniquely identified in the discovery
analysis and replicated by EWASmin−P . Pm1 and Pv1 are P -values from CpG site-level mean and
variance tests that are adjusted for multiple comparisons for the number of CpGs in the gene from
the discovery analysis, and Pm2 and Pv2 are those from the replication analysis. Highlighted are
the minimum adjusted DM and DV P -value across all P -values in the gene in each comparison. The
four horizontal lines represent mean methylation levels of the four groups of tissues.
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C.1 Additional Simulation Studies
C.1.1 Effects of gene sizes in Type I errors
To investigate if genes with different sizes, i.e., number of CpGs, will have different distri-
butions for pseudo-F statistics under the null hypothesis, we conducted simulation studies
to evaluate type I error rates of the proposed method and those of the comparison methods.
Specifically, we simulated methylation measures for 16 genes that consist of 1, 5, 10, 15,
20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, and 100 CpGs, respectively. When calculating the
P -value for each gene, we (1) pool all pseudo-F statistics of the 16 genes across all permu-
tations, and (2) only use pseudo-F statistics of that particular gene across all permutations.
Type I error rate is defined as the proportion of simulations with any significant genes when
the data is generated under the null hypothesis of no genes are associated with case-control
status.
Table C.1: Type I error rates in simulation settings with multiple genes of different sizes
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Figure C.1: Power results for simulation settings with main signals only, interaction signals only
and both main and interaction signals when there are (A) 20 CpGs, (B) 30 CpGs, and (C) 40 CpGs
in a gene.
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C.1.3 Simulation settings with fixed number of signal items coming from
different number of signal CpGs
C.1.3.1 Simulation setup
Table C.2: Simulation settings with 4 signal items and the same signal composition (2 main
and 2 interaction signals) but from 2∼4 signal CpGs
Number of Signal CpGs and settings Simulation setupa
2 signal CpGs: βX1 = βX3 = βZ1 = βZ3 = 0.3
2 CpGs with main + interaction signals
3 signal CpGs:
1 CpG with main + interaction signals; βX1 = βX3 = βZ3 = βZ5 = 0.3
1 CpG with main signal only;
1 CpG with interaction signal only
4 signal CpGs:
2 CpGs with main signal only; βX1 = βX3 = βZ5 = βZ7 = 0.3
2 CpGs with interaction signal only
aX represents DNA methylation main effects, Z represents DNA methylation by environment interaction
effects.
APPENDIX C. APPENDIX TO A POWERFUL AND FLEXIBLE WEIGHTED
DISTANCE-BASED METHOD INCORPORATING INTERACTIONS BETWEEN DNA
METHYLATION AND ENVIRONMENTAL FACTORS ON HEALTH OUTCOMES 120
C.1.3.2 Simulation results
When the 4 signal items are set with 2 main signals and 2 interaction signals and increasing
the number of signal CpGs from 2 to 4, the power of Dw-main, Dmain and LS that considers
main signals only increases slightly as expected. The power of Dw-main-int and Dmain-int
that considers both main and interaction signals also increases as the number of signal
CpGs increases, while that of LM decreases. For methods Dw-int and Dint that considers
interaction signals only, we observe the largest power when there are 3 signal CpGs, slightly
lower/similar power when there are 4 signal CpGs, and lowest power when there are 2 signal
CpGs. The non-monotone trend might due to the fact that the 2 CpGs with interaction
signals were randomly set in the data matrix Xmain-int. That is, the 2 CpGs with main
signals were fixed to be the 1st and 3rd CpGs in the gene, while the 2 CpGs with interaction
signals were chosen at different locations in the gene in each setting. Overall, the power of
Dw-int and Dint increases as the number of signal CpGs increases, and the weighted versions






















































Correlation Among Signal CpGs
Figure C.2: Power results for simulation settings where there are 2 main signal items and 2 inter-
action signal items coming from 2, 3 and 4 signal CpGs, respectively when there are 30 CpGs in a
gene.
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C.2 Real data applications
C.2.1 DNA methylation data processing
DNA methylation in the MN cohort was measured in 432 cord blood samples, for which 168
had data from the 450K array with 485,577 CpG sites and 264 from the EPIC array with
866,895 CpG sites. DNA methylation data in the Sibling cohort was measured from 67 cord
blood samples, for which 40 had data from the 450K array and 27 from the EPIC array.
For methylation data, we conducted standard quality control steps where we removed CpGs
on sex chromosomes and those contain either a single nucleotide polymorphism (SNP) at
the CpG interrogation or at the single nucleotide extension (SBE) based on UCSC dbSNP
table version 147 using the R package ‘IlluminaHumanMethylation450kanno.ilmn12.hg19’
(Hansen, 2015). We further required at least 95% CpG coverage per sample and 70% sample
coverage per CpG, and corrected for the type II probe bias using the ‘wateRmelon’ package
(Pidsley et al., 2013). We then calibrated the 450K data to EPIC distribution (Horvath,
2013), and only kept overlapping CpG sites that were covered by both arrays which also
had gene annotations, leaving 263,574 common CpG sites covering 18,633 genes in both
MN and Sibling methylation datasets. We then transformed the methylation measures to
M -values by taking logit2 transformation, and applied linear regression models on M -values
at each CpG to adjust for cell proportions estimated from the ‘minfi’ package (Aryee et al.,
2014) and obtained the M -value residuals. We then applied the proposed method and all
comparison methods to the M -value residuals in the following analyses.
APPENDIX C. APPENDIX TO A POWERFUL AND FLEXIBLE WEIGHTED
DISTANCE-BASED METHOD INCORPORATING INTERACTIONS BETWEEN DNA
METHYLATION AND ENVIRONMENTAL FACTORS ON HEALTH OUTCOMES 122
C.2.2 Risk of PAH, DNA methylation and their interactions on ADHD
























































































































Figure C.3: Boxplot of DNA methylation measures of the 9 CpGs in gene LOC84931 stratified by
ADHD status in the (A) discovery analysis using the MN cohort, and the (B) replication analysis
using the Sibling cohort. Here p(m) and p(i) are Bonferroni-adjusted (for number of CpGs in gene
LOC84931 ) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model: logitP (Y = 1) =
β0 + β1CpG + β2E + β3CpG× E.
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Figure C.4: Boxplot of DNA methylation measures of the 4 CpGs in gene HIST1H2BJ stratified
by ADHD status in the (A) discovery analysis using the MN cohort, and the (B) replication analysis
using the Sibling cohort. Here p(m) and p(i) are Bonferroni-adjusted (for number of CpGs in gene
HIST1H2BJ ) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model: logitP (Y = 1) =
β0 + β1CpG + β2E + β3CpG× E.
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C.2.2.2 Results from the comparison methods
Table C.3: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 11 genes by Dw-main at the 0.005 gene-level P -value
threshold
Rank in Dw-main Gene # CpG Rank in Dw-main-int
1 LOC84931 * 9 1
2 SERPINB3 * 1 2
3 HIST1H2BJ * 4 9
4 IGJ * 1 7
5 ADAM32 * 11 8
6 TRIM38 7 33
7 SPDYC 9 17
8 NDUFA5 9 16
9 BICD1 14 15
10 KRTAP20-1 * 1 6
11 CXCL9 * 1 10
*Genes also identifed by Dw-main-int.
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Table C.4: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 14 genes by Dw-int at the 0.005 gene-level P -value
threshold
Rank in Dw-int Gene # CpG Rank in Dw-main-int
1 CYP2E1 * 13 3
2 MIR518E * 1 4
3 KIR3DP1 * 1 5
4 GBAP1 6 27
5 MAS1 2 14
6 ARHGEF15 9 100
7 LRIT2 7 24
8 OR8G1 1 22
9 WASH2P 1 12
10 OR2AE1 3 54
11 OR2T27 1 35
12 HNMT 5 37
13 TNFRSF10B 11 49
14 MIR604 2 19
*Genes also identifed by Dw-main-int.
Table C.5: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 5 genes by Dmain-int at the 0.005 gene-level P -value
threshold
Rank in Dmain-int Gene # CpG Rank in Dw-main-int
1 LOC84931 * 9 1
2 CYP2E1 * 13 3
3 MIR518E * 1 4
4 SERPINB3 * 1 2
5 SPACA1 6 11
*Genes also identifed by Dw-main-int.
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Table C.6: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 8 genes by Dmain at the 0.005 gene-level P -value threshold
Rank in Dmain Gene # CpG Rank in Dw-main-int
1 LOC84931 * 9 1
2 SPACA1 6 11
3 CRISP2 10 40
4 SERPINB3 * 1 2
5 IGJ * 1 7
6 RBM46 12 66
7 KRTAP20-1 * 1 6
8 CXCL9 * 1 10
*Genes also identifed by Dw-main-int.
Table C.7: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 11 genes by Dint at the 0.005 gene-level P -value threshold
Rank in Dint Gene # CpG Rank in Dw-main-int
1 MIR518E * 1 4
2 KIR3DP1 * 1 5
3 CYP2E1 * 13 3
4 OR8G1 1 22
5 WASH2P 1 12
6 OR2T27 1 35
7 SPRYD5 1 20
8 UCHL5 1 60
9 GK3P 1 78
10 MAS1 2 14
11 TAS2R3 1 82
*Genes also identifed by Dw-main-int.
APPENDIX C. APPENDIX TO A POWERFUL AND FLEXIBLE WEIGHTED
DISTANCE-BASED METHOD INCORPORATING INTERACTIONS BETWEEN DNA
METHYLATION AND ENVIRONMENTAL FACTORS ON HEALTH OUTCOMES 127
Table C.8: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 4 genes by LS at the 0.005 gene-level P -value threshold
Rank in LS Gene # CpG Rank in Dw-main-int
1 LOC84931 * 9 1
2 ADAM32 * 11 8
3 TRIM38 7 33
4 SERPINB3 * 1 2
*Genes also identifed by Dw-main-int.
Table C.9: Application examining prenatal PAH, DNA methylation and their interactions
on child ADHD at age 3 identified 4 genes by LM at the 0.005 gene-level P -value threshold
Rank in LM Gene # CpG Rank in Dw-main-int
1 UBASH3B 23 106
2 MYH2 8 41
3 JARID2 84 590
4 TNFRSF10B 11 49
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The seven comparison methods Dw-main, Dw-int, Dmain-int, Dmain, Dint, LS and LM
identified 11, 14, 5, 8, 11, 4, 4 genes and replicated 2, 2, 2, 0, 3, 0, 0 genes (replication
rate ranges 0-40% with a mean of 14%). These results are summarized in Supplementary
Table C.10. The 2 genes, LOC84931 and HIST1H2BJ, replicated by Dw-main, as well as the
2 genes, LOC84931 and CYP2E1, replicated by Dmain-int, were all identified and replicated
by the proposed method due to main/interaction signals. The gene CYP2E1 was repli-
cated by Dw-int, Dint and Dmain-int, and was also identified and replicated by the proposed
method due to interaction signals. The other gene, WASH2P, that was also replicated by
both Dw-int and Dint, was ranked #12 (P -value=0.0056) in the proposed method Dw-main-int
results in the discovery analysis. In general, the genes replicated by the comparison meth-
ods were either all replicated or ranked on top in the Dw-main-int results. This suggests that
the proposed method that incorporates both main and interaction signals indeed has better
performance.
Table C.10: Summary number of genes identified at the 0.005 gene-level P -value threshold
and replicated at the 0.1 gene-level P -value threshold in the application examining prenatal
PAH, DNA methylation and their interactions on child ADHD at age 3
Method
# of gene replicated /
identified in discovery data
Replicated genes
Dw-main-int 3/10 LOC84931, CYP2E1, HIST1H2BJ
Dw-main 2/11 LOC84931, HIST1H2BJ
Dw-int 2/14 CYP2E1, WASH2P
Dmain-int 2/5 LOC84931, CYP2E1
Dmain 0/8 -
Dint 3/11 CYP2E1, WASH2P, UCHL5
LS 0/4 -
LM 0/4 -
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C.2.3 Risk of PAH, DNA methylation and their interactions on MDI
Table C.11: Summary number of genes identified at the 0.005 gene-level P -value threshold
and replicated at the 0.1 gene-level P -value threshold in the application examining prenatal
PAH, DNA methylation and their interactions on child MDI at age 3
Method
# of gene replicated /
identified in discovery data
Replicated genes
Dw-main-int 4/7 FAM35A, DIRC1, C8orf80, THSD1P




Dint 3/12 GSTA1, OR4P4, FAM166B
LS 0/3 -
LM 0/3 -
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Figure C.5: Boxplot of DNA methylation measures of the 7 CpGs in gene FAM35A stratified by
MDI status in the (A) discovery analysis using the 2/3 MN discovery data, and the (B) replication
analysis using the 1/3 MN replication data. Here p(m) and p(i) are Bonferroni-adjusted (for number
of CpGs in gene FAM35A) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model:
logitP (Y = 1) = β0 + β1CpG + β2E + β3CpG× E.
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Boxplot	of	DNA	Methylation	Measure	Stratified by	MDI	(cut	at	85)	for	the	Gene	DIRC1
(A)	3 CpGs in	the	Gene	DIRC1 in	the	Discovery	Data

















































































Figure C.6: Boxplot of DNA methylation measures of the 3 CpGs in gene DIRC1 stratified by
MDI status in the (A) discovery analysis using the 2/3 MN discovery data, and the (B) replication
analysis using the 1/3 MN replication data. Here p(m) and p(i) are Bonferroni-adjusted (for number
of CpGs in gene DIRC1 ) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model:
logitP (Y = 1) = β0 + β1CpG + β2E + β3CpG× E.
APPENDIX C. APPENDIX TO A POWERFUL AND FLEXIBLE WEIGHTED
DISTANCE-BASED METHOD INCORPORATING INTERACTIONS BETWEEN DNA
































































































Figure C.7: Boxplot of DNA methylation measures of the 5 CpGs in gene THSD1P stratified by
MDI status in the (A) discovery analysis using the 2/3 MN discovery data, and the (B) replication
analysis using the 1/3 MN replication data. Here p(m) and p(i) are Bonferroni-adjusted (for number
of CpGs in gene THSD1P) P -values testing β1 = 0 and β3 = 0 in the multiple logistic model:
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